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Abstract!
! !
! Of the components of the respiratory system, one of the most crucial is the 
pulmonary surfactant. This mixture of phospholipids, cholesterol, and proteins act to 
reduce surface tension inside the lungs as well as fight infection. The surfactant 
associated proteins vary in their structure and function but the most important is 
surfactant protein B (SP-B) which is essential to life. Despite its importance, it has not 
yet been structurally characterized and as a result, its function still remains a mystery. 
Part of the problem is the difficulty in acquiring enough of the protein to work with. To 
attempt to solve this problem, a method has been developed to recombinantly express 
a variant of human SP-B in Escherichia coli in relative abundance. Also, a series of 
functional tests on the recombinant SP-B were completed to determine if it is a viable 
alternative to native SP-B for use in the laboratory and possible clinical applications. 
The functional tests included membrane leakage and lipid mixing assays, as well as 
captive bubble surfactometer studies. These experiments revealed that the recombinant 
SP-B displayed normal SP-B activity albeit not as effective as native SP-B. !
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1.! Introduction!
!
1.1 Respiratory System / Gas Exchange"
! Oxygen (O2) is an essential component of many cellular processes. Most 
organisms including humans have to take in oxygen from the environment to meet this 
requirement. There also has to be a way of expelling carbon dioxide (CO2), which is a 
common byproduct of metabolism. Both of these essential tasks take place in the 
respiratory system. Humans as well as other mammals have a respiratory system that 
centers on the lungs.!
! The lungs are very important organs in the mammalian respiratory system. They 
are so important, two out of the four chambers of the heart are dedicated to pumping 
blood to and from the lungs. As the deoxygenated blood moves into the lungs, it passes 
through progressively smaller blood vessels. Eventually they reach capillaries that are 
so thin that only one red blood cell can pass through at a time. The walls of these 
capillaries consist of an endothelium which is only one cell thick. These features provide 
a very efficient way for the gases to be exchanged between the blood and the 
environment.!
!  Once in the lungs, inhaled air passes through increasingly smaller passages 
culminating in small sac-like structures known as alveoli (Figure 1). This inhalation is 
brought about by the expansion of the chest cavity by several muscles but mostly the 
diaphragm and muscles surrounding the ribcage. The obverse of this is exhalation and 
involves similar muscle groups contracting the chest cavity. This creates a positive 
internal pressure in the lungs which forces the air out. !
 1
! !
Figure 1: Schematic showing the inside of an alveolus and the position of lung 
surfactant inside.  
 2
surfactant film
! During this process, gas exchange occurs in the alveoli. This is where the 
capillaries of the pulmonary circulation come into close contact with the inhaled air. The 
alveolar surface is coated with a 0.2 μm thick layer of water through which the 
respiratory gasses can diffuse 1. While this water layer is a great system for preventing 
the dehydration of alveolar tissue, it does create the inherent problem of surface 
tension. Surface tension is a phenomena brought about when the molecules on the 
surface of a fluid are more attracted to each other than the external environment. Water 
has an especially high surface tension due to water molecules being exceptionally polar. 
The normal surface tension of water is approximately 70 mN/m. This creates a particular 
problem for the lungs. If left unchecked, the surface tension of the fluid layer in the 
alveoli would cause them to collapse 2. This effect would be even more pronounced 
during the increased pressure of exhalation. Collapsed alveoli require a lot of work to be 
forced back open. Surface tension can be reduced if amphipathic molecules known as 
surfactant are arranged along the air-water interface (Figure 1). Being amphipathic, 
these molecules can interact with both the polar water and non-polar air space, which 
reduces the effect of surface tension. The lungs create their own surfactant called 
pulmonary surfactant.!
!
!
!
 3
1.2 Pulmonary Surfactant" !
! Pulmonary surfactant is produced by the alveolar type II epithelial cells 3. Its 
composition is comprised of mostly phospholipids, cholesterol and proteins (See Table 
1). The phospholipids comprise 80% of the total mass of the pulmonary surfactant and 
make up the bulk of the amphipathic molecules that sit along the air-water interface in 
alveoli. These phospholipids are most responsible for lowering surface tension. A 
significant portion of the phospholipid fraction are phosphatidylglycerol (PG) species 
making up 10% the total mass of the surfactant 4. These have negatively charged head 
groups and are responsible for giving pulmonary surfactant an overall negative charge 
which is probably important for the interaction between surfactant and positively 
charged surfactant proteins (see below). By far the most common phospholipid found in 
surfactant, however, is phosphatidylcholine (PC) species, which takes up approximately 
70% of the total surfactant mass 5. About half of this is dipalmitoylphosphatidylcholine 
(DPPC) 4. DPPC is a phospholipid that contains choline, a zwitterionic head group and 
therefore has an overall neutral charge. The hydrophobic part consists of two palmitoyl 
chains, which are saturated fatty acids.  These fatty acids allow for the tight packing of 
pulmonary surfactant, important during the compression of alveoli 6. The problem with 
DPPC in biological membranes is that they have a relatively high melting point (~41°C). 
At the physiological temperature of 37°C, this would lead to tight packing of lipids which 
is important for the surfactant to reduce surface tension 7. However, the tight packing 
results in reduced mobility which creates a problem when the surfactant must spread 
across the air-water interface. The mobility of lipids in surfactant is increased by the 
presence of unsaturated phospholipids and cholesterol, which comprises approximately 
 4
10% of the surfactant mass. However, the movement of surfactant to the interface is 
mostly dependent on the hydrophobic surfactant proteins, which make up about 3% 8 9. 
The remaining 7% is occupied by the hydrophilic surfactant proteins 10.!
!
 5
!
Table 1: Composition of Adult Human Lung Surfactant 4 5 8 9 10
Category Component Percentage !
(by weight)
!!!!
Phospholipids (~85%)
Phosphatidylcholine (PC) ~70%
Phosphatidylglycerol (PG)!
Phosphatidylinositol (PI)!
(acidic phospholipids)
~15%
Phosphatidylethanolamine (PE)!
Phosphatidylserine (PS)!
Sphingomyelin (SM)
!
Minor
!
Neutral Lipids (~5%)
Cholesterol ~5%
Glycerides!
Free Fatty Acids
Minor
!!!
Proteins (~10%)
Surfactant Protein A (SP-A) ~6%
Surfactant Protein B (SP-B) ~1.5%
Surfactant Protein C (SP-C) ~1.5%
Surfactant Protein D (SP-D) ~1%
 6
! A current model for pulmonary surfactant synthesis has the surfactant excreted 
from the Type II cells as lamellar bodies (LB) into the external water layer of alveoli 
(Figure 2) 3 11. Once outside the cells, these lamellar bodies become hydrated and 
unravel into an ordered crosshatched structure of tubules known as tubular myelin (TM) 
12. Pulmonary surfactant in tubular myelin structures could spread directly onto the air-
water interface as a surface active film 13 14. However, it is more probable that they form 
a multi-layered, three dimensional structure of lipids 3 8. This multi-layered structure is 
associated with the surface active film and can act as a form of lipid reservoir 15. These 
structures are stabilized by the hydrophobic surfactant proteins. ! !
!
 7
!  !
Figure 2: Models for the secretion and absorption of pulmonary surfactant. Adapted 
from Figure 2, Perez-Gil and Weaver, 2010 with permission from the publisher 16. 
rated phospholipids (DPPC) segregate into ordered
micro- and nano-domains, which can be highly
compressed to produce the requisite low surface ten-
sion; unsaturated phospholipids and surfactant pro-
teins remain in disordered regions that facilitate
rapid transfer of phospholipids into (and out of) the
surface film (22a, 27a, 115). Comingling of or-
dered and disordered domains thus provides a
potential mechanism for maintenance of a stable
interfacial film.
Although we have a basic understanding of sur-
factant film dynamics, many details of the under-
lying processes remain unclear. It is assumed that
DPPC enrichment of the surface film is required to
support maximal pressures (very low surface ten-
sions) at end expiration, but the actual proportion
of DPPC that reaches the interfacial film is not
known. Some studies suggested that SP-B and
SP-C could selectively promote insertion of DPPC
(99) into the interfacial film, but direct proof for
this activity is lacking. It has been also proposed
that compression of the surface film during expi-
ration induces progressive refining of the interfa-
cial film by squeezing out less stable unsaturated
species, leading to DPPC enrichment (28, 64, 76).
Direct examination of the structure and composi-
tion of the surface film formed from native surfac-
tant under physiologically relevant conditions is
required to confirm or discard these hypotheses. It
is currently thought that the ability of surfactant to
produce very low tensions during breathing is de-
pendent on formation of a multilayered film at the
interface (6, 36, 88). However, a comparison of the
rheological properties of multilayered vs. monolay-
ered surfactant films is required to test this model.
Finally, an active line of research has tried to assign
specific activities to SP-B and SP-C in remodeling
of interfacial surfactant films during compression
and facilitating film re-spreading during expansion
(see FIGURE 3). Consistent with the neonatal lethal
phenotype of SP-B-deficient mice, in vitro ap-
proaches using devices that capture some of the
physiological compression-expansion constraints
of the respiratory interface revealed that SP-B is
required to achieve and sustain the lowest tensions
during compression. SP-C, on the other hand, may
cooperate in facilitating interfacial surfactant dy-
namics, including folding of the surface film, main-
taining the multilayer reservoir attached to the
interface during compression and promoting effi-
cient re-spreading of the film on expansion. Opti-
mal performance of surfactant at the interface may
therefore require cooperation of both hydrophobic
surfactant proteins (1). Validation of thesemodels in
vivo requires the development of new genetically
modified animal models that are not yet available.
Surfactant Recycling and Surfactant
Homeostasis
Compression-expansion cycling leads to progres-
sive conversion of the surface active fractions of
FIGURE 2. Pulmonary surfactant adsorption to the interface and surface film formation
Processes that may contribute to transport of surface active surfactant species to the interface include 1) direct coop-
erative transfer of surfactant from secreted lamellar body-like particles touching the interface, 2) unraveling of se-
creted lamellar bodies to form interm d ate structures uch as tubular myelin (TM) or large surfactant layers that have
the potential to move and transfer large amounts of material to the interface, and 3) rapid movement of surface ac-
tive species through a continuous network of surfactant membranes, a so-called surface phase, connecting secreting
cells with th interface.
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of i terfacial surfactant films during compression
and facilitating film re-spreading during expansion
(see FIGURE 3). Consistent with the neonatal lethal
phenotype of SP-B-deficient mice, in vitro ap-
proaches using devices that capture some of the
physiological compr ssion-expansion constraints
of the respiratory interface revealed that SP-B is
requ red to achieve and sustain the lo est tensions
duri g compression. SP-C, on the other hand, may
cooperate in facilitating interfacial surfactant dy-
amics, including folding of the surface film, main-
taining the multilayer reservoir attached to the
interface during compression and promoting effi-
cient re-spreading of the film on expansion. Opti-
mal performance of surfactant at the interface may
therefore require cooperation of both hydrophobic
surfa tant proteins (1). Validation of thesemodels in
vivo requires the development of new genetically
modified animal models that are not yet available.
Surfactant Recycling and Surfactant
Homeostasis
Compression-expansion cycling leads to progres-
sive conversion of the surface active fractions of
FIGURE 2. Pulmonary surfactant adsorption to the interface and surface film formation
Processes that may contribute to transport of surface active surfactant species to the interface include 1) direct coop-
erative transfer of surfactant from secreted lamellar body-like particles touching the interface, 2) unraveling of se-
creted lamellar bodies to form intermediate structures such as tubular myelin (TM) or large surfactant layers that have
the potential to move and transfer large amounts of material to the interface, and 3) rapid movement of surface ac-
tive species through a continuous network of surfactant membranes, a so-called surface phase, connecting secreting
cells with the interface.
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(see FIGURE 3). Consistent with the neonatal lethal
phenotype of SP-B-deficient mice, in vitro ap-
proaches using devices that capture some of the
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of the respiratory interface revealed that SP-B is
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during compression. SP-C, on the other hand, may
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namics, including folding of the surface film, main-
taining the multilayer reservoir attached to the
interface during compression and promoting effi-
cient re-spreading of the film on expansion. Opti-
mal performance of surfactant at the interface may
therefore require co peration of both hydrophobic
surfactant proteins (1). Validation of thesemodels in
vivo requires the development of new genetically
modified animal models that are not yet available.
Surfactant Recycling and Surfactant
Homeostasis
Compression-expansion cycling leads to progres-
sive conversion of the surface active fractions of
FIGURE 2. Pulmonary surfactant adsorption to the interface and surface film formation
Processes that may contribute to transport of surface active surfactant species to the interface include 1) direct coop-
erative transfer of surfactant from secreted lamellar body-like particles touching the interface, 2) unraveling of se-
creted lamellar bodies to form in ermediate structures such as tubular myelin (TM) or large surfactant layers that have
the potential to move and transfer large amounts of material to the interface, and 3) rapid movement of surface ac-
tive species through a continuous n work of surfactant membranes, a so-called surface phase, connecting secreting
cells with the interface.
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! During breathing, the surface area of the air-water interface changes. During 
exhalation when the surface area is smallest, the pulmonary surfactant will be forced 
away from the interface (Figure 3). During inhalation, the surface area increases again 
and must be once again coated with pulmonary surfactant. These multi-layered, surface 
associated structures would fulfill these requirements in that they can provide a way for 
the surfactant to be stored during exhalation. They also allow for efficient re-spreading 
of the surfactant during inhalation. The formation and stability of these structures are 
thus of great physiological importance 8 17.!
!
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  !
!
Figure 3: The hydrophobic surfactant proteins and their interactions with surfactant 
layers during compression and expansion. Adapted from Figure 3, Perez-Gil and 
Weaver, 2010 with permission from the publisher 16. 
surfactant into much less active lipid/protein
complexes (43, 95). Inactivation probably includes
detachment of small particulate entities from the
interface, changes in lipid/protein organization,
and oxidation of lipid and protein species on re-
petitive exposure to air (83). Surfactant may also be
inactivated by incorporation of materials inhaled
from the upper airways or leaked from capillaries
(42, 114). Maintenance of a fully functional surfac-
tant film therefore requires continual film refine-
ment through efficient removal of spent surfactant
and incorporation of newly secreted complexes. It
remains unclear whether the distinct surfactant
structures that coexist in the alveolar pool are spe-
cifically targeted to functional, recycling, or clear-
ance pathways.
Surfactant homeostasis requires coordinated
regulation of the processes summarized in
FIGURE 1. The alveolar surfactant pool is contin-
uously depleted through cellular uptake by type
II epithelial cells and alveolar macrophages as
well as removal via the mucociliary escalator. It is
unclear whether cellular uptake of alveolar surfac-
tant occurs indiscrimately or whether there is se-
lective targeting of specific forms of surfactant to
type II cells for recycling and/or macrophages for
degradation. Preliminary support for selective up-
take of alveolar surfactant by type II cells comes
from recent studies in SP-D-deficient mice (50, 51).
Interaction of the collectin SP-D with PI-rich sur-
factant complexes altered surfactant structure and
enhanced uptake by type II cells but not macro-
phages. Thus, in addition to its well documented
role in host defense, SP-D plays an important role
in regulating alveolar pool size.
The loss of surfactant from the airspaces is bal-
anced by secretion of surfactant stored in lamellar
bodies: regulation of surfactant secretion is there-
fore critical for homeostasis. Several excellent, re-
cent reviews provide a comprehensive analysis of
surfactant secretion and the central role of calcium
mobilization in this process (4, 29). However, al-
though pharmacological and physical stimuli of sur-
factant secretion have been extensively characterized,
FIGURE 3. Participation of proteins SP-B and SP-C in surfactant dynamics during respiratory com-
pression-expansion cycling
Hydrophobic surfactant proteins play key roles in facilitating optimal dynamic behavior of surfactant during breathing.
During exhalation, the surfactant surface film folds through three-dimensional transitions, forming a complex structure
that sustains maximal pressures. Protein SP-C facilitates compression-driven folding of surfactant interfacial films (1),
expulsion of lipids and lipid/protein complexes from the interface (80, 92), and formation of three-dimensional phases
(59, 101, 102). SP-B stabilizes the interfacial film (2) and promotes establishment of membrane-membrane contacts
(22, 24, 86), leading to formation of multilayered membrane arrays (3) (17). SP-B seems to provide mechanical stabil-
ity to compressed films (23), possibly through increasing cohesivity between surfactant layers during maximal com-
pression of the surface film. SP-C could promote association of excluded surfactant structures with the maximally
compressed interface, likely through its NH2-terminal segment and/or insertion of palmitoylated cysteines of the pro-
tein into tightly packed interfacial films (4) (11, 102). Finally, both SP-B (23, 90, 106) and SP-C (73, 74, 81) seem to
promote insertion (5) and re-spreading (6) of phospholipids from subsurface compartments into the interface during
expansion.
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take of alveolar surfactant by type II cells comes
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phages. Thus, in addition to its well documented
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in regulating alveolar pool size.
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cent reviews provide a comprehensive analysis of
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mobilization in this process (4, 29). However, al-
though pharmacological and physical stimuli of sur-
factant secretion have been extensively characterized,
FIGURE 3. Participation of proteins SP-B and SP-C in surfactant dynamics during respiratory com-
pression-expansion cycling
Hydrophobic surfactant proteins play key roles in facilitating optimal dynamic behavior of surfactant during breathing.
During exhalation, the surfactant surface film folds through three-dimensional transitions, forming a complex structure
that sustains maximal pressures. Protein SP-C facilitates compression-driven folding of surfactant interfacial films (1),
expulsion of lipids and lipid/protein complexes from the interface (80, 92), and formation of three-dimensional phases
(59, 101, 102). SP-B stabilizes the interfacial film (2) and promotes establishment of membrane-membrane contacts
(22, 24, 86), leading to formation of multilayered membrane arrays (3) (17). SP-B seems to provide mechanical stabil-
ity to compressed films (23), possibly through increasing cohesivity between surfactant layers during maximal com-
pression of the surface film. SP-C could promote association of excluded surfactant structures with the maximally
compressed interface, likely through its NH2-terminal segment and/or insertion of palmitoylated cysteines of the pro-
tein into tightly packed interfacial films (4) (11, 102). Finally, both SP-B (23, 90, 106) and SP-C (73, 74, 81) seem to
promote insertion (5) and re-spreading (6) of phospholipids from subsurface compartments into the interface during
expansion.
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inactivated by incorporation of materials inhaled
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and incorporation of newly secreted complexes. It
remains unclear whether the distinct surfactant
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cifically targeted to functional, recycling, or clear-
ance pathways.
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unclear whether cellular uptake of alveolar surfac-
tant occurs indiscrimately or whether there is se-
lective targeting of specific for s of surfactant to
type II cells for recycling and/or macrophages for
degradation. Preliminary support for selective up-
take of alveolar surfactant by type II cells comes
from recent studies in SP-D-deficient mice (50, 51).
Interaction of the collectin SP-D with PI-rich sur-
factant complexes altered surfactant structure and
enhanced uptake by type II cells but not macro-
phages. Thus, in addition to its well documented
role in host defense, SP-D plays an important role
in regulating alveolar pool size.
The loss of surfactant from the airspaces is bal-
anced by secretion of surfactant stored in lamellar
bodies: regulation of surfactant secretion is there-
fore critical for homeostasis. Several excellent, re-
cent reviews provide a comprehensive analysis of
surfactant secretion and the central role of calcium
mobilization in this process (4, 29). However, al-
though pharmacological and physical stimuli of sur-
factant secretion have been extensively characterized,
FIGURE 3. Participatio of proteins SP-B and SP-C in surfactant dynamics during respiratory com-
pression-exp nsion cycling
Hydrophobic surfactant proteins play key roles in facilitating opti al dy mic behavior f surfactant during breathing.
During exhalation, th surfactant surface film folds through three-dimensional transitions, formi g a complex structure
that sustains maximal pressures. Pr tein SP-C facilitates compression-driven f lding f surfactant int rfacial films (1),
expulsion of lipids and lipid/protein complexes from the interface (80, 92), and formation of three-dimensional phases
(59, 101, 102). SP-B stabilizes the interf cial fil (2) and promotes establishment of membrane-membrane contacts
(22, 24, 86), leading to formation of multilayered membrane arrays (3) (17). SP-B seems to provide mech nical stabil-
ity to compressed films (23), possibly through increasing c hesivity between surfactant layers during i l com-
pression of the surface film. SP-C could promote association of exclud d surfactant structures with the maximally
compressed interface, likely through its NH2-terminal segment and/or insertion of palmitoylated cysteines of the pro-
t in into tightly packed interfacial films (4) (11, 102). Fin lly, both SP-B (23, 90, 106) a d SP-C (73, 74, 81) seem to
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type II cells for recycling and/or macrophages for
degradation. Preliminary support for selective up-
take of alveolar surfactant by type II cells comes
from recent studies in SP-D-deficient mice (50, 51).
Interaction of the collectin SP-D with PI-rich sur-
factant complexes altered surfactant structure and
enhanced uptake by type II cells but not macro-
phages. Thus, in addition to its well documented
role in host defense, SP-D plays an important role
in regulating alveolar pool size.
The loss of surfactant from the airspaces is bal-
anced by secretion of surfactant stored in lamellar
bodies: regulation of surfactant secretion is there-
fore critical for homeostasis. Several excellent, re-
cent reviews provide a comprehensive analysis of
surfactant secretion and the central role of calcium
mobilization in this process (4, 29). However, al-
though pharmacological and physical stimuli of sur-
factant secretion have been extensively characterized,
FIGURE 3. Participation of proteins SP-B and SP-C in surfactant dynamics during respiratory com-
pression-expansion cycling
Hydrophobic surfactant proteins play key roles in facilitating optimal dynamic behavior of surfactant during breathing.
During exhalation, the surfactant surface film folds through three-dimensional transitions, forming a complex structure
that sustain maximal pressures. Protein SP-C facilitates compression-driven folding of surfactant interfacial films (1),
expulsi n of lipids and lipid/protein complexes from the interface (80, 92), and formation of three-dimensional phases
(59, 101, 102). SP-B stabilizes the interfacial film (2) and promotes establishment of membrane-membrane contacts
(22, 24, 86), leading to formation of multilayered membrane arrays (3) (17). SP-B seems to provide mechanical stabil-
ity to compressed films (23), possibly through increasing cohesivity between surfactant layers during maximal com-
pression of the surface film. SP-C could promote association of excluded surfactant structures with the maximally
compressed interface, likely through its NH2-terminal segment and/or insertion of palmitoylated cysteines of the pro-
tein into tightly packed interfacial films (4) (11, 102). Finally, both SP-B (23, 90, 106) and SP-C (73, 74, 81) seem to
promote insertion (5) and re-spreading (6) of phospholipids from subsurface compartments into the interface during
expansion.
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surfactant into much less active lipid/protein
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detachment of small particulate entities from the
interface, changes in lipid/protein organization,
and oxidation of lipid and protein species on re-
petitive exposure to air (83). Surf ctant m y also be
inactivated by incorporation of materials inhaled
from the upper airways or leaked from capillaries
(42, 114). Maintenance of a fully functional surfac-
tant film therefore requires continual film refine-
ment through efficient removal of spent surfactant
and incorporation of newly secreted complexes. It
remains unclear whether the distinct surfactant
structures that coexist in the alveolar pool are spe-
cifica ly targeted to fu ctional, r cycling, o clear-
ance pathways.
Surfactant homeostasis requires coordinated
regulation of the processes summarized in
FIGURE 1. The alveolar surfactant pool is co tin-
uously depleted through cellular uptake by type
II epithelial cells and alveolar macrophages as
well as removal via the mucociliary escalator. It is
unclear whether cellular uptake of alveolar surfac-
tant occurs indiscrimately or whether there is se-
lective targeting of specific forms of surfactant to
type II cells for recycling and/or macrophages for
degradation. Preliminary support for selective up-
take of alveol r surfactant by type II cells com s
from recent studies in SP-D-deficient mice (50, 51).
Inter ction of the collectin SP-D with PI-rich su -
factant complexes altered surfactant structure and
enhanced uptake by type II cells but not macro-
phages. Thus, in addition to its well documented
role in host defense, SP-D plays an important role
in regulating alveolar pool size.
The loss of surfactant from the airspaces is bal-
anced by secretion of surfactant stored in lamellar
bodies: regulation of surfactant secretion is there-
fore critical for homeostasis. Several excellent, re-
cent reviews provide a comprehensive analysis of
surfactant secretion and the central role of calcium
mobilization in this process (4, 29). However, al-
though pharmacological and physical stimuli of sur-
factant secretion have been extensively characterized,
FIGURE 3. Participation of proteins SP-B and SP-C in surfactant dynamics during respiratory com-
pression-expansion cycling
Hydrophobic surfactant proteins play key roles in facilitating optimal dynamic behavior of surfactant during breathing.
During exhalation, the surfactant surface film folds through three-dimensional transitions, forming a complex structure
that sustains maximal pressures. Protein SP-C facilitates compression-driven folding of surfactant interfacial films (1),
expulsion of lipids and lipid/protein complexes from the interface (80, 92), and formation of three-dimensional phases
(59, 101, 102). SP-B stabilizes the interfacial film (2) and promotes establishment f membrane-membrane contacts
(22, 24, 86), leading to formation of multilayered membrane arrays (3) (17). SP-B seems to provide mechanical stabil-
ity to compressed films (23), possibly through increasing cohesivity between surfactant layers during maximal com-
pression of the surface film. SP-C could promote association of excluded surfactant structures with the maximally
compressed interface, likely through its NH2-terminal segment and/or insertion of palmitoylated cysteines of the pro-
tein into tightly packed interfacial films (4) (11, 102). Finally, both SP-B (23, 90, 106) and SP-C (73, 74, 81) seem to
promote insertion (5) and re-spreading (6) of phospholipids from subsurface compartments into the interface during
expansion.
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petitive exposure to air (83). Surfactant may also be
inactivated by incorporation of materials inhaled
from the upper airways or leaked from capillaries
(42, 114). Maintenance of a fully functional surfac-
tant film therefore requires continual film refine-
ment through efficient removal of spent surfactant
and incorporation of newly secreted complexes. It
remains unclear whether the distinct surfactant
structures that coexist in the alveolar pool are spe-
cifically targeted to functional, recycling, or clear-
ance pathways.
Surfactant homeostasis requires coordinated
regulation of the processes sum arized in
FIGURE 1. The alveolar surfactant pool is contin-
uously depleted through cellular uptake by type
II epithelial cells and alveolar macrophages as
well as removal via the mucociliary escalator. It i
unclear whether cellular uptake of alveolar surfac-
tant occurs indiscrimately or whether there is se-
lective targeting of specific forms of surfactant to
type II cel s for recycling and/o macrophages for
degradation. Pr liminary support for selective up-
take of alveolar s rfactant by type II cells comes
from recent studies in SP-D-deficient mice (50, 51).
Interaction of the c llectin SP-D with PI-rich sur-
factant complexes altered surfactant structure and
enhanc d uptake by type II cells but ot macro-
phages. Thus, in addition to its well documented
role in host defense, SP-D plays an important role
in regulating lveolar pool siz .
The loss of surfacta t fro the a rspaces is bal-
anced by secretion of surfactant stored in lamellar
bodies: regulation of surfactant secretion is there-
fore critical for homeostasis. Several excellent, re-
c nt revi ws provide a comprehensive analysis of
surfactant secretion and the central role of calcium
mobilization in this process (4, 29). However, al-
though pharmacological and physical stimuli of sur-
fa tant secretion ave be n extensively characterized,
FIGURE 3. Participation of proteins SP-B and SP-C in surfactant dynamics during respiratory com-
pression-expansion cycling
Hydrophobic surfactant proteins play key roles in facilitating optimal dynamic behavior of surfactant during breathing.
During exhalation, the surfactant surface film folds through three-dimensional transitions, forming a complex structure
that sustains maximal pressures. Protein SP-C facilitates compression-driven folding of surfactant interfacial films (1),
expulsion of lipids and lipid/protein complexes from the interface (80, 92), and formation of three-dimensional phases
(59, 101, 102). SP-B stabilizes the interfacial film (2) and promotes establishment of membrane-membrane contacts
(22, 24, 86), leading to formation of multilayered membrane arrays (3) (17). SP-B seems to provide mechanical stabil-
ity to compressed films (23), possibly through increasing cohesivity between surfactant layers during maximal com-
pression of the surface film. SP-C could promote association of excluded surfactant structures with the maximally
compressed interface, likely through its NH2-terminal segment and/or insertion of palmitoylated cysteines of the pro-
tein into tightly packed interfacial films (4) (11, 102). Finally, both SP-B (23, 90, 106) and SP-C (73, 74, 81) seem to
promote insertion (5) and re-spreading (6) of phospholipids from subsurface compartments into the interface during
expansion.
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factant complexes altered surfactant structure and
enhanced uptake by type II cells but not macro-
phages. Thus, in addition to its well documented
role in host defense, SP-D plays an important role
in regulating alveolar pool size.
The loss of surfactant from the airspaces is bal-
anced by secretion of surfactant stored in lamellar
bodies: regulation of surfactant secretion is there-
fore critical for homeostasis. Several excellent, re-
cent reviews provide a comprehensive analysis of
surfactant secretion and the central role of calcium
mobilization in this process (4, 29). However, al-
though pharmacological and physical stimuli of sur-
factant secretion have been extensively characterized,
FIGURE 3. Participation of proteins SP-B and SP-C in surfactant dynamics during respiratory com-
pression-expansion cycling
Hydrophobic surfactant proteins play key roles in facilitating optimal dynamic behavior of surfactant during breathing.
During exhalation, the surfactant surface film folds through three-dimensional transitions, forming a complex structure
that sustains maximal pressures. Protein SP-C facilitates compression-driven folding of surfactant interfacial films (1),
expulsion of lipids and lipid/protein complexes from the interface (80, 92), and formation of ree-dimensional phases
(59, 101, 102). SP-B stabilizes the interfacial film (2) and promotes establishment of membrane-membrane contacts
(22, 24, 86), leading to formation of multilayered membrane arrays (3) (17). SP-B seems to provide mechanical stabil-
ity to compressed films (23), possibly through increasing cohesivity between surfactant layers during maximal com-
pression of the surface film. SP-C could promote association of excluded surfactant structures with the maximally
compressed interface, likely through its NH2-terminal segment and/or insertion of palmitoylated cysteines of the pro-
tein into tightly packed interfacial films (4) (11, 102). Finally, both SP-B (23, 90, 106) and SP-C (73, 74, 81) seem to
promote insertion (5) and re-spreading (6) of phospholipids from subsurface compartments into the interface during
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FIGURE 3. Participation of proteins SP-B and SP-C in surfactant dynamics during respiratory com-
pression-expansion cycling
Hydrophobic surfactant proteins play key roles in facilitating optimal dynamic behavior of surfactant during breathing.
During exhalation, the surfactant surface film folds through three-dimensional transitions, forming a complex structure
that ustains maximal pressures. Protein SP-C facilitates compression-driven folding of surfactant interfacial films (1),
expulsion of lipids and lipid/protein complexes from the interface (80, 92), and formation of three-dimensional phases
(59, 101, 102). SP-B stabilizes the interfacial film (2) and promotes establishment of membrane-membrane contacts
(22, 24, 86), leading to formation of multilayered membrane arrays (3) (17). SP-B seems to provide mechanical stabil-
ity to compressed films (23), possibly through increasing cohesivity between surfactant layers during maximal com-
pression of the surface film. SP-C could promote association of excluded surfactant structures with the maximally
compressed interface, likely through its NH2-terminal segment and/or insertion of palmitoylated cysteines of the pro-
tein into tightly packed interfacial films (4) (11, 102). Finally, both SP-B (23, 90, 106) and SP-C (73, 74, 81) seem to
promote insertion (5) and re-spreading (6) of phospholipids from subsurface compartments into the interface during
expansion.
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1.3 Surfactant Proteins"
! There are four surfactant proteins: surfactant protein A, B, C, and D (SP-A, SP-B, 
SP-C, SP-D). They were named chronologically with A being the first discovered and D 
being the last 18. SP-A and SP-D are hydrophilic and mostly function as part of the 
innate immune defence system. SP-B and SP-C are small hydrophobic proteins that 
directly interact with the surface active films.!
! Along with reducing surface tension, pulmonary surfactant can help defend 
against inhaled pathogens. The lungs have a large surface area that is regularly 
exposed to the environment. To help combat this, the surfactant has evolved an immune 
function along with the surface active function. Its position along the air-water interface 
establishes a barrier that pathogens have difficulty getting past to reach the epithelial 
cells. Also, surfactant proteins A and D have been shown to have innate immune 
properties 19 20 21.!
! SP-A is the most abundant pulmonary surfactant protein. It consists of a 
carbohydrate-recognition domain and a collagen domain that forms a trimer 22. Six of 
these trimers come together to form an octadecamer in aqueous solution, a structure 
that is consistent with the collectin family of proteins 23 24 22. However, it has also been 
found to form smaller conformations when interacting with lipid or detergent micelles 25. 
SP-A has the ability to bind to many possible ligands including Ca2+, phospholipids, and 
carbohydrates allowing the protein to bind to a wide variety of pathogens including 
bacteria, viruses, and fungi 24 26. It can also attract alveolar macrophages to the 
pathogens in order to remove them 27. Knockout of the SP-A gene causes increased 
vulnerability to infection 26. Despite its relative abundance, the lack of a working SP-A 
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gene does not result in impaired breathing 28. This suggests it is not essential to the 
surface activity of pulmonary surfactant. However, experiments show that SP-A assists 
in the formation of surface active films together with SP-B and SP-C. Also, these films 
perform better during compression-expansion dynamics when SP-A is present which 
suggests a cooperative function of SP-A by interacting with the hydrophobic surfactant 
proteins 29 30.  !
! SP-D is another member of the collectin family 22. Its structure consists of a 
collection of trimers similar to SP-A. The quaternary structure of SP-D however, only 
consists of four trimers as opposed to the six in SP-A 10. Both the structures of SP-A and 
SP-D were studied using X-ray crystallography for the CRD domains. Electron 
microscopy was used to complete the structure 31 32. Knockout of the SP-D gene also 
leads to a marked increase in the vulnerability to infection. However, this knockout has 
no observable effect on surface activity indicating that the presence SP-D is not 
important to surfactant function 33. SP-D has been shown in vivo to help regulate the 
lipid homeostasis of surfactant 22.!
!  Along with the immune function associated with SP-A and SP-D, surface tension 
reduction by pulmonary surfactant is also essential. Surface tension relies on the 
hydrophobic surfactant proteins SP-B and SP-C 8.  !
! SP-C is a small, 35 residue alpha-helical peptide. As well as having many 
hydrophobic amino acids, it also has two sites of palmitoylation near the carboxy-
terminus 34. They combine to make SP-C one of the most hydrophobic proteins known. 
These features allow SP-C to interact directly with the lipid portion of the pulmonary 
surfactant. Through this interaction, SP-C could be helping to stabilize the multi-layered 
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surfactant reservoir and also aid in the spreading of surface active films 8 35. Despite this 
important function, the presence of a working SP-C gene is not necessary to start air-
breathing life. Mice with a knockout of the SP-C gene display normal gas exchange and 
surfactant function 36 37. The presence of SP-B could be sufficient for surfactant to 
function normally. In humans however, SP-C deficiency has been found to lead to 
chronic lung impairment 38. The full structure of SP-C in an organic solvent (chloroform/
methanol), was determined through nuclear magnetic resonance (NMR) spectroscopy 
39. NMR was used instead of X-ray crystallography due to the inherent difficulty in 
getting hydrophobic proteins to crystallize. This difficulty is also seen with the other 
hydrophobic surfactant protein: SP-B.!
! !
1.4 Surfactant Protein B!
! SP-B is the most important surfactant protein. It is the only surfactant protein 
whose deficiency is absolutely fatal 40 41. SP-B is first synthesized as a soluble 
propeptide. It is processed to its mature form in the alveolar type II epithelial cells. This 
processing involves the action of multiple enzymes including pepsinogen C, cathepsin 
H, napsin A, and possibly others 42 43 44 45. The mature SP-B is a 79 residue, 8.7 kDa 
hydrophobic protein (Table 2). Like SP-C, it is one of the most hydrophobic proteins 
known. It is more hydrophobic than many integral membrane proteins. It also contains 
many cationic residues which give SP-B an overall +7 charge at neutral pH. Being 
positively charged could help SP-B interact with the large proportion of negatively 
charged lipids that form part of the pulmonary surfactant 46. !
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! Most of what is currently known about SP-B function has arisen from biophysical 
experiments with SP-B isolated from lung lavages from porcine or bovine sources. It 
has been shown to promote membrane binding, fusion, and leakage 47 48 49. SP-B can 
also be observed assisting the absorption spreading of lipid films to an air-water 
interface 50 51. Any or all of these activities could be the mechanism of SP-Bs 
contribution to the surface activity of pulmonary surfactant. Many current models have 
SP-B assisting the formation and stabilization of the multi-layered films that form 
underneath the air-water interface during exhalation 52. It also facilitates the re-
spreading of the surface active film during inhalation 53 54. Unfortunately, the mechanism 
of SP-B is incompletely understood due mostly to the lack of a three-dimensional 
structure. !
! SP-B is a member of the saposin superfamily of small lipid-binding proteins 55 56. 
SP-B has either four or five alpha helices. These are held together by three disulfide 
bonds between cysteine residues. This is a structure that is similar to proteins of the 
saposin family 57. SP-B isolated from lung lavages has an observed size of about 17 
kDa leading to the suggestion that it can form a dimer that is held together with an 
intermolecular disulfide bond 55. While this much about SP-B structure is known, the full 
tertiary structure still remains a mystery. The difficulty with finding the structure of SP-B 
will be discussed below.!
!
!
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Table 2: Amino acid sequence of mature human surfactant protein B (SP-B)!
1-10 Phe - Pro - Ile - Pro - Leu - Pro - Tyr - Cys - Trp - Leu
11-20 Cys - Arg - Ala - Leu - Ile - Lys - Arg - Ile - Gln - Ala
21-30 Met - Ile - Pro - Lys - Gly - Ala - Leu - Ala - Val - Ala
31-40 Val - Ala - Gln - Val - Cys - Arg - Val - Val - Pro - Leu
41-50 Val - Ala - Gly - Gly - Ile - Cys - Gln - Cys - Leu - Ala
51-60 Glu - Arg - Tyr - Ser - Val - Ile - Leu - Leu - Asp - Thr
61-70 Leu - Leu - Gly - Arg - Met - Leu - Pro - Gln - Leu - Val
71-79 Cys - Arg - Leu - Val - Leu - Arg - Cys - Ser - Met
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1.5 Pulmonary Surfactant Disorders"
! Being of such vital importance, impairment of pulmonary surfactant can lead to a 
detrimental effect on gas exchange and lung function in general. There are several 
disorders that involve pulmonary surfactant but the most common are respiratory 
distress syndrome (RDS), and acute respiratory distress syndrome (ARDS).!
! RDS is also commonly known as neonatal respiratory distress syndrome due to it 
affecting babies who have had a premature birth. If born without enough time to 
properly develop a functional pulmonary surfactant, breathing can be extremely 
impaired 58. RDS can currently be treated with a combination of mechanical ventilation 
and the application of exogenous surfactant. This treatment only has to last long 
enough for the infants to produce their own surfactant normally. Treatment with 
exogenous surfactant has decreased the mortality rate of premature birth by half. 
However, RDS remains the leading cause of death of premature infants 59. !
! The exogenous surfactant used in treatment for RDS usually comes from natural 
sources. These sources are commonly bovine and include the most common 
exogenous treatment in Canada: bovine lipid extracted surfactant (BLES) 60. The 
composition of surfactant from this source is similar to normal human surfactant with the 
exception of the hydrophilic proteins (SP-A and SP-D) and neutral lipids (glycerides, 
cholesterol). The BLES does contain the hydrophilic proteins SP-B and SP-C which are 
crucial to surface activity. The sequence of the surfactant proteins are highly conserved 
amongst species. The relative expense of BLES is not an obstacle here, at least in 
developed countries, because of the very small amount needed to saturate premature 
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lungs. This is not the case for the surfactant disorders afflicting adults including ALI and 
ARDS.!
! ALI and the more severe ARDS are acute disorders which lead to the inactivation 
of pulmonary surfactant. There can be many different causes for this. These include 
inflammation, mechanical stress, oxidative stress, or the leakage of blood serum 
proteins into the alveolar space 61. ARDS is much more complicated to treat than RDS. !
! Mechanical ventilation leads to problems in that the stress can exacerbate the 
condition. In fact, people who are hooked up to mechanical ventilators for a significant 
amount of time can develop ARDS 62. Treatment with exogenous surfactant is very 
difficult. Unlike neonatal lungs, adult lungs are much larger and require much more 
surfactant to be effective. Also, people with ARDS likely already have collapsed alveoli 
which need more surfactant to force them open. Both of these reasons cause sufferers 
of ARDS to require a lot of exogenous surfactant for it to have a chance to be effective. 
Natural sources of surfactant are much too expensive to provide a viable treatment 63. 
An artificial source of a surfactant treatment has long been a goal of surfactant 
researchers. To date, no artificial surfactant treatments have shown any improvement 
for ARDS patients 64. This is partly due to the conditions already present in the lungs 
during ARDS also inactivating the exogenous surfactant 65. Furthermore, the inability to 
artificially produce SP-B, which is critical to proper surfactant function, reduces the 
efficacy of any artificial surfactant treatment. For these reasons, with current treatments, 
the mortality rate from ARDS is 50% 66. The development of an artificial source for SP-B 
could lead to artificial surfactant that could act as a successful treatment for ARDS. 
Also, it would support solving the three-dimensional structure of SP-B which could lead 
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to a better understanding of its mechanism and result in the development of new ARDS 
treatments.!
!
1.6 Structural Studies of Proteins"
! As mentioned before, the most common method for the structural determination 
of proteins is X-ray crystallography. This is a powerful tool that can determine protein 
structure down to the atomic level. Unfortunately, this method requires proteins to be 
crystallized in an ordered fashion. With the right conditions, this can be done relatively 
easily with soluble proteins. Hydrophobic proteins, however, are resistant to crystal 
formation, partly because the detergents that are commonly used to isolate hydrophobic 
proteins prevent crystal lattice formation 67 68. For this reason, only 1% of protein 
structures in the Protein Data Bank (PDB) are hydrophobic or membrane proteins 68. 
SP-B is an extremely hydrophobic peptide. As a result of this, all attempts to produce an 
SP-B crystal have failed.  !
! The other method most commonly used to determine protein structure is solution 
NMR. Specifically, this is done using techniques such as three dimensional total 
correlation spectroscopy (TOCSY) and nuclear Overhauser effect spectroscopy 
(NOESY). Application of these techniques to all but the smallest proteins requires the 
replacement of the carbon and nitrogen atoms of a protein with 13C and 15N isotopes. 
These isotopes have half-spin nuclei and can produce a signal with NMR. These spins 
can interact with each other through-bond (TOCSY) and through-space (NOESY). The 
frequencies of the pairs of nuclei involved in these interactions are then determined, a 
process called "assignment". Then, the NOESY spectra are used to generate a long list 
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of pairs of hydrogen nuclei that are close in space. With enough of these distance 
restraints, a computer program can calculate possible structures of the protein 69 70. The 
advantage of this technique over X-ray crystallography is that there is no crystallization 
requirement and hydrophobic proteins can be analyzed in the presence of lipid or 
detergent micelles. Interaction with these micelles would provide a more physiologically 
relevant structure as many hydrophobic proteins like SP-B interact with lipids. The main 
disadvantage is the need for 13C and 15N labelled protein. These can be obtained 
through the recombinant expression of the protein in E.coli. !
!
1.7 Recombinant Expression of Proteins"
! The recombinant expression of proteins is a common artificial source for 
proteins. If the genetic sequence of the protein is known, that gene can then be inserted 
into a bacterial expression vector which can then be transfected into an E.coli culture. 
These plasmids vary depending on the protein being expressed but they usually contain 
some common features including resistance to a certain antibiotic (such as ampicillin or 
kanamycin) and a promoter than can act as a genetic “switch”. The antibiotic resistance 
is to reduce competition and contamination from other bacteria. When grown in the 
presence of the antibiotic, only the bacteria that contain the plasmid should grow 71.  
The promoter is used to achieve some control over the expression of the gene of 
interest. In many cases, this promoter is the lac operon. This is a promoter already 
found in some bacterial species. In the presence of lactose, the promoter is activated, 
leading to the expression of genes involved with lactose metabolism. In recombinant 
systems, the lac operon is placed in front of the gene of interest.  Instead of lactose, an 
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analog known as isopropyl-β-D-1-thiogalactopyranoside (IPTG) is used. Like lactose, 
IPTG can activate the lac operon and thus induce expression of the gene. Unlike 
lactose, it will not degrade, resulting in a constant concentration of IPTG over the course 
of protein expression 72. This system of continuous activation of the gene is known as 
over-expression and produces much more protein than the E.coli would normally 
produce. This induction also inhibits bacterial growth as all available resources are used 
to produce the protein. !
! Several variables have to be optimized in order to maximize protein yield, such 
as the timing of induction, which is usually done during the log phase of bacterial 
growth. Next, the concentration of IPTG to use for induction must be determined and 
finally, the expression time must also be optimized. While there is usually some idea of 
the appropriate ranges for each variable, the optimization requires a lot of trial and error 
73. !
! Recombinant expression in E.coli is very efficient in producing soluble proteins. 
However, problems arise when trying to over-express hydrophobic proteins. 
Recombinant hydrophobic proteins can be toxic to the E.coli through possible 
competition with native membrane proteins and disruption of the membrane as a whole 
68 73. Because of this, it is difficult to get large yields of recombinant hydrophobic 
proteins. There are, however, techniques to overcome these difficulties. First, several 
bacteria strains have been developed to resist the toxicity of hydrophobic proteins. One 
of these strains, C43, directs the expressed proteins into inclusion bodies making them 
incapable of membrane disruption 74. Also, the protein can be expressed as a fusion 
with a large hydrophilic protein which would increase the solubility of the protein being 
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over-expressed and prevent it from disrupting the bacterial membrane. Common fusion 
partners include maltose binding protein (MBP), glutathione S-transferase (GST) and 
staphyloccal nuclease (SN) 73 75 76.!
!
1.8 Purification of Recombinant Proteins"
! The next step in producing recombinant protein is to purify it from native E.coli 
proteins as well as other biomolecules such as lipids and DNA. The cells can be lysed 
through various methods including the use of a French press and sonication. Different 
cellular components can be separated through the use of different solvents and 
centrifugation. It is possible to enrich the sample from the soluble, membrane, and 
insoluble inclusion bodies fractions. Depending on the nature of the expressed protein, 
it can be located in one or more of these fractions and should be located before further 
work. !
! The recombinant protein can be further purified using affinity chromatography. 
Some hydrophilic fusion proteins also have a binding function. Taking advantage of this 
fact, chromatography resin loaded with a ligand specific for the fusion protein can be 
used to isolate the fusion complex. These fusions include MBP and GST which bind to 
maltose and glutathione respectively 73 75. Alternatively, recombinant proteins can be 
isolated through the use of a histidine tag. A sequence of at least six histidine (6xHis) 
residues can bind to a nickel charged resin in a technique known as immobilized metal 
affinity chromatography (IMAC) 77. The 6xHis tag can be expressed as a part of the 
protein. Using these chromatography methods, the recombinant protein (as a fusion or 
otherwise) can be sufficiently enriched. !
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! If the recombinant protein was expressed without any fusions then this would be 
the final step. However, if the protein was expressed with a fusion protein then this must 
be removed before most structural studies can be done. To facilitate this, a cleavage 
site located between the fusion and the protein of interest is usually included in the 
design of the gene. This site is a particular sequence that can be targeted for cleavage 
by either enzymatic or chemical means. Enzymatic cleavage makes use of protease to 
cleave the fusion. Common proteases used in this way are trypsin, thrombin, and 
tobacco etch virus (TEV) protease 76 78 79. These reactions have to take place under 
gentle buffer conditions so the enzyme remains folded and functional. However, under 
these conditions, hydrophobic proteins tend to aggregate which can block enzymatic 
action. One way around this is to switch to chemical cleavage which takes place under 
much more severe conditions. The most commonly used method of chemical cleavage 
uses cyanogen bromide (cleaves after methionine residues), which reacts in a solution 
of 70% formic acid 67. Under these conditions, the fusion protein should be entirely 
unfolded and the cleavage sites sufficiently exposed. Another chemical that is routinely 
used for chemical cleavage is hydroxylamine 80. While generally more efficient, the 
conditions for chemical cleavage renders proteins completely denatured and they must 
be carefully refolded to properly function. !
! The fusion construct has to be designed so that the specific cleavage site is not 
found anywhere in the protein of interest. If this were the case, the protein would get 
cleaved into pieces. For example, because cyanogen bromide cleaves after methionine 
residues, the protein cannot have any internal methionines. In this case, another 
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proteolytic agent would be used or the internal methionines could be mutated to another 
similar amino acid 67. !
! After proteolysis has taken place, the protein must be separated from the 
hydrophilic fusion protein. There might also be some undigested fusions present that 
must be removed if the reaction wasn’t 100% efficient which is often the case. The 
separation may require many different techniques including organic extraction and 
chromatography. The production of a recombinant fusion protein and its subsequent 
purification is discussed in detail in this thesis.!
!
1.9 Recombinant Expression of SP-B"
! Recombinant expression would be an excellent artificial source for SP-B for both 
research and clinical applications. It is a relatively cheap and quick way to produce 
proteins. Manipulation of the gene would permit the introduction of mutations allowing 
certain residues to be changed. Through observing the impact of these changes on SP-
B function, we can gain some insight into which residues are critically important. Gene 
manipulation will also have applications in the clinical sense as certain genes can be 
designed to produce an SP-B derivative that is more resistant to inactivation in ARDS 
which can lead to possible treatment options. Furthermore, the E.coli can be grown in a 
media containing only 13C and 15N carbon and nitrogen sources producing the isotope-
labelled SP-B that is required for NMR structural studies. Of course, before any 
expression can be attempted, a plasmid construct must be designed.!
!
!!
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1.10 Designing the Plasmid Construct"!
! The first step of recombinant expression is to design the plasmid that will be used 
to transfect the bacterial cells. Several things must be considered. First of all, will the 
protein of interest poison the bacteria? As mentioned above, hydrophobic proteins have 
a tendency to interfere with the normal expression in bacterial systems. Expressing the 
protein is only part of the process as the protein must also be isolated from the other 
bacterial proteins and other molecules including lipids. !
! The work presented in this thesis can be traced to work done with expression of 
SP-C 76. Like SP-B, SP-C is a very hydrophobic protein and the expression was 
facilitated by expressing the SP-C as a fusion with staphylococcal nuclease (SN), which 
is a large hydrophilic protein. The purification was accomplished through the use of a 
poly-histidine tag at the amino-terminus of the fusion and a thrombin cleavage site was 
placed between the two proteins to remove the SN. To try and replicate the successful 
expression of SP-C with SP-B, the plasmid was modified to replace SP-C with SP-B. 
This plasmid was first produced by the Jesus Perez-Gil lab at the Universidad 
Complutense de Madrid and passed on to our lab. Attempts to produce a full length 
recombinant SP-B with this plasmid was discussed in the thesis of Mahzad 
Sharifahmadian 81, and did not yield high expression levels of SP-B. As suggested, a 
new gene was designed to attempt to improve expression.!
! This new gene, designated SN-Δ7NTΔM-SP-B-6His, was designed with several 
new features to aid in the expression and purification of SP-B (Figure 4). First of all, the 
thrombin cleavage site was removed in favour of a cyanogen bromide cleavage site (a 
methionine residue). The use of a cyanogen bromide digest also required the removal 
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of the internal methionines in SP-B which were changed to leucines similar to the work 
done in Gong et al. 67. Another change to the SP-B was made in that the seven amino-
terminal residues (FPIPLPY) were removed to aid in the expression as suggested by 
Sharifahmadian 81. Finally, the 6-histidine tag was moved from the amino-terminus of 
the SN to the carboxy-terminus of the SP-B. The SP-B and 6-his tag were separated by 
another cyanogen bromide cleavage site to facilitate the removal of the tag. !
! The work presented here will demonstrate a new effort to express SP-B 
recombinantly using this new gene. The hypothesis is that these genetic modifications 
will allow SP-B to be expressed in an E. coli system. The goal is to express and purify 
SP-B for structural studies and for inclusion in improved therapeutics for ARDS. !
!
!
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Figure 4: The SN-Δ7NTΔM-SP-B-6His plasmid construct (both the nucleotide sequence 
and amino acid sequence of the expressed fusion).  
SN-Δ7NTΔM-SP-B-6His-codop
CATATGGCAACTTCAACTAAAAAATTACATAAAGAACCTGCGACTTTAATTAAAGCGATTGATG
    M  A  T  S  T  K  K  L  H  K  E  P  A  T  L  I  K  A  I  D    
GTGATACGGTTAAATTAATGTACAAAGGTCAACCAATGACATTCAGACTATTATTGGTTGATAC
G  D  T  V  K  L  M  Y  K  G  Q  P  M  T  F  R  L  L  L  V  D  T
ACCTGAAACAAAGCATCCTAAAAAAGGTGTAGAGAAATATGGTCCTGAAGCAAGTGCATTTACG
  P  E  T  K  H  P  K  K  G  V  E  K  Y  G  P  E  A  S  A  F  T
AAAAAAATGGTAGAAAATGCAAAGAAAATTGAAGTCGAGTTTGACAAAGGTCAAAGAACTGATA
 K  K  M  V  E  N  A  K  K  I  E  V  E  F  D  K  G  Q  R  T  D 
AATATGGACGTGGCTTAGCGTATATTTATGCTGATGGAAAAATGGTAAACGAAGCTTTAGTTCG
K  Y  G  R  G  L  A  Y  I  Y  A  D  G  K  M  V  N  E  A  L  V  R
TCAAGGCTTGGCTAAAGTTGCTTATGTTTACAAACCTAACAATACACATGAACAACATTTAAGA
  Q  G  L  A  K  V  A  Y  V  Y  K  P  N  N  T  H  E  Q  H  L  R
AAAAGTGAAGCACAAGCGAAAAAAGAGAAATTAAATATTTGGAGCGAAGACAACGCTGATTCGG
 K  S  E  A  Q  A  K  K  E  K  L  N  I  N  S  E  D  N  A  D  S  
GCCTGATGTGCTGGCTGTGCCGCGCGCTGATCAAACGCATCCAGGCCCTGATTCCGAAAGGTGC
G  L  M  C  W  L  C  R  A  L  I  K  R  I  Q  A  L  I  P  K  G  A  
GCTGGCTGTGGCAGTGGCCCAGGTGTGCCGCGTGGTGCCGCTGGTGGCGGGCGGCATCTGCCAG
  L  A  V  A  V  A  Q  V  C  R  V  V  P  L  V  A  G  G  I  C  Q  
TGCCTGGCGGAACGCTATAGCGTGATCCTGCTGGATACCCTGCTGGGCCGCCTGCTGCCGCAGC
 C  L  A  E  R  Y  S  V  I  L  L  D  T  L  L  G  R  L  L  P  Q  
TGGTGTGCCGCCTGGTCCTGCGTTGCAGCATGCACCATCACCACCATCATTAAGGATCC
L  V  C  R  L  V  L  R  C  S  M  H  H  H  H  H  H  STOP
    =SN
    =Δ7NTΔM-SP-B
    =NdeI restriction site
    =BamH1 restriction site
    =6His tag
Notes:
SN-SP-B fusion protein with a C-term 6His ag. T SP-B contains 
a 7 amino acid deletion of the N-terminus as well as 2 point 
mutations (21M"L, 58M"L). Ha  a Met residue between the SN and 
SP-B as well as between the SP-B and 6His tag to facilitate CNBr 
cleavage. Also contains Nde1 and BamH1 restriction sites. 
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! !
2.! Materials and Methods!
!
2.1 SDS Polyacrylamide Gel Electrophoresis (PAGE)"
! SDS PAGE was used throughout this work 82. Two types of gels were used, a 
precast, 16.5% polyacrylamide gel (Mini-PROTEAN Tris Tricine Precast Gel, Bio-Rad, 
Hercules, CA, USA) and a hand-cast 18% polyacrylamide gel. The 18% gels were 
prepared by first creating a separating gel by mixing 6 mL of a 30% acrylamide, 0.8% 
bis-acrylamide solution with 4 mL separating buffer (91.3 g/L Tris, 2.1 g/L SDS, pH = 
8.8). 100 μL ammonium persulfate (10%) and 20 μL tetramethylethylenediamine 
(TEMED) was then added and mixed well. The resulting solution was poured between 
two gel plates leaving enough room for the stacking gel. 50% ethanol was poured on 
top and the separating gel was allowed to set. Once set, the ethanol was discarded and 
the top of the gel was washed with deionized water. A stacking gel was prepared by 
mixing 0.65 mL of a 30% acrylamide, 0.8% bis-acrylamide solution with 4.35 mL 
stacking buffer (16.18 g/L Tris, 1.2 g/L SDS, 0.1 g/L sodium azide, pH = 6.8). 100 μL 
ammonium persulfate (10%) and 20 μL TEMED was then added and mixed well. The 
stacking gel was then poured on top of the separating gel. Before setting, a comb was 
placed in the stacking gel to create sample wells. After the stacking gel was set, the gels 
were either used immediately or stored in the fridge overnight. !
! The gels were placed in an electrophoresis tank which was filled with the 
appropriate running buffer: SDS buffer (2.4 g/L Tris, 11.25 g/L glycine, 1 g/L SDS, 0.1 g/
L sodium azide) for the hand-cast 18% gels or Tris Tricine buffer (Bio-Rad, Hercules, 
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CA, USA) for the precast gels. Protein samples were dissolved in sample buffer (13% 
glycerol, 1.97 g/L Tris, 3.25 g/L SDS, 0.1 g/L sodium azide, 0.02% bromophenol blue) 
with or without a reducing agent (dithiothreitol (DTT)). These samples were then heated 
in boiling water for 2-3 minutes, and once cooled, applied to the gel. Two molecular size 
markers were usually loaded onto the gels as well. The markers were the Precision Plus 
Kaleidoscope Protein Standards and the Kaleidoscope Polypeptide Standards (Bio-
Rad, Hercules, CA, USA).!
! The gel was run at 80 V until the tracking dye reached the separating gel at 
which point the voltage was increased to 180 V until the tracking dye reached the 
bottom of the gel. The gels were either stained with Coomassie Brilliant Blue (CBB) 
R-250 or silver.!
!
2.1.1 CBB R-250 Staining"
! Completed gels were placed in a staining solution (0.25% CBB R-250, 40% 
ethanol, 7% glacial acetic acid) and agitated for 45 minutes. The gels were then 
transferred to a destaining solution (10% ethanol, 7% glacial acetic acid) and agitated 
until the protein bands were visible and the background was clear.!
!
2.1.2 Silver Staining"
! Completed gels were placed in a fixing solution (40% ethanol, 10% glacial acetic 
acid) and agitated for 30 minutes. The gel was then transferred to an incubating solution 
(30% ethanol, 68 g/L sodium acetate trihydrate, 2 g/L sodium thiosulfate, 0.1% 
gluteraldehyde) and agitated for another 30 minutes. The gel was washed three times 
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with deionized water and placed in a silver solution (1 g/L silver nitrate) and agitated for 
a further 40 minutes. The gel was rinsed once with deionized water and placed into a 
developing solution (25 g/L sodium carbonate) until the bands were evident (5-15 
minutes). The reaction was stopped by placing the gel in stop solution (14.6 g/L 
disodium ethylenediamine tetraacetate (EDTA)) and agitated for 15 minutes.!
!
2.2 Western Blot"
! Western blot analysis was also used throughout this work 83. Electrophoresis was 
performed as described above but instead of staining, the finished gel was placed in 
transfer buffer (10 mM CAPS,10% methanol, pH = 11) and agitated for 30 minutes. A 
polyvinylidene fluoride (PVDF) membrane (Millipore Corporation, MA, USA) was cut out 
and rinsed once with methanol, three times with deionized water, then soaked in 
transfer buffer for 30 minutes. Both the gel and membrane were placed in the 
electrophoresis apparatus and the protein was transferred to the membrane by applying 
a voltage of 60 V for two hours. Once complete, the gel was discarded and the 
membrane was soaked in a blocking solution (2% milk in TTBS) for one hour. After 
three washes with TTBS (150 mM Tris ,50 mM NaCl, 0.05% Tween-20 at pH = 7.6), the 
gel was soaked in a primary antibody solution overnight. In this research, the primary 
antibody used was an anti-SP-B rabbit antibody (Seven Hills Bioreagents, Cleveland, 
OH, USA) diluted 1:5000 in TTBS. The next morning, the primary antibody was 
decanted and stored in a -4°C freezer. The membrane was washed twice with TTBS 
and a secondary antibody was applied and stirred for one hour. An anti-rabbit IgG with 
alkaline phosphatase (Sigma-Aldrich, St. Louis, MO, USA) diluted 1:5000 in TTBS was 
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used. The secondary antibody is discarded and the membrane washed twice with 
TTBS. The colour reaction is performed in the dark using a solution of 60 μL BCIP and 
120 μL NBT in 20 mL TTBS. Once complete, the colour reaction is stopped using Tris-
EDTA (TE) buffer (10 mM Tris, 1 mM EDTA, pH = 8) All stages of this procedure were 
performed at 20°C.!
!
2.3 Transformation of Plasmids into Cell Line"
" 1μL of the 1 ng/μL plasmid DNA was added to 50μL of C43 (DE3) competent 
cells in a prechilled tube. The mixture was incubated on ice for 30 minutes then heat 
shocked at 42°C for 45 seconds. This was followed by a further incubation of 2 minutes, 
once again on ice. 500μL of 2xYT broth (16g/L tryptone, 10g/L yeast extract, and 5g/L 
NaCl at pH 7) preheated to 42°C was added to the cells and this was incubated at 37°C, 
175 rpm for 1 hour. After incubation, the transformation mixture was plated onto two 
2xYT agar plates containing ampicillin and incubated overnight at 37°C.!
!
2.4 Determining the Cellular Extract Fraction Where the Expressed SN-Δ7NTΔM-SP-
B-6His is Located"
! To ascertain in which cellular extract fraction the expressed SN-Δ7NTΔM-SP-
B-6His fusion protein is located, a smaller scale expression was prepared. A small 
sample of transfected C43 cells was placed in 10 mL 2xYT broth + 0.1 mM ampicillin 
and incubated overnight at 37°C and 175 rpm. The overnight culture was then used to 
inoculate 1 L of 2xYT broth with 0.1 mM ampicillin in a 4 L flask. The flask was 
incubated at 37°C and 175 rpm until the OD600 (optical density at 600 nm) reached 
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approximately 0.6. The cells were induced with 0.4 mM IPTG and returned to the 
shaking incubator for a further 3 hours at 37°C. Induction was halted by centrifuging the 
cells suspension at 5000 rpm for 15 minutes at 4°C upon which the cells were 
resuspended in a Tris buffered saline (TBS) buffer + 5 mM phenylmethylsulfonylflouride 
(PMSF). The TBS buffer consists of 150 mM Tris and 50 mM NaCl at pH = 7.6. The 
cells were then lysed by passing them twice through a French press at 12,000 psi and 
the total extract was divided into three equal portions to correspond to the three different 
cellular extract fractions. These samples were not centrifuged. Sample 1 contained the 
extract in TBS buffer, sample 2 contained the extract in TBS buffer + 0.5% lauroyl 
sarcosine (LS), and sample 3 contained the extract in TBS buffer + 0.5% LS + 6 M urea.!
! To each sample, imidazole (5M stock) was added to 20mM and three nickel-
charged IMAC columns (see below) were prepared, one for each sample. These 
columns were equilibrated with the appropriate solvent conditions + 20mM imidazole. 
Each sample blot was applied to a column at 20°C and washed with starting buffer. Any 
fusion protein was eluted using the starting buffer + 300mM imidazole. The relative 
amount of the fusion protein in each sample was determined by applying a portion (10 
μL) of each sample to an 18% polyacrylamide gel (SDS PAGE).!
!
2.5 Large Scale Expression of SN-Δ7NTΔM-SP-B-6His"
! A small sample of transfected C43 cells were placed in 75 mL 2xYT broth + 0.1 
mM ampicillin and incubated overnight at 37°C and 175 rpm. The next morning, 10 mL 
of the starting culture was added to each of six 4 L flasks containing 1 L of 2xYT broth + 
0.1mM ampicillin. The flasks were incubated at 37°C and 175 rpm until the OD600 
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reached approximately 0.6. The cells were induced with 0.4 mM IPTG and returned to 
the shaking incubator for a further 3 hours. Induction was halted by centrifuging the cell 
suspension at 5000 rpm for 15 minutes at 4°C upon which the cells were resuspended 
in a TBS buffer + 5mM PMSF and frozen at -20°C until ready to lyse. The procedure 
changed for cell lysis during which the sonication step was eliminated and three passes 
through a French press at 12,000 psi was utilized. After lysis, no centrifugation takes 
place but LS and urea were added to the total cellular extract to make a concentration 
of 0.5% w/w and 6M respectively. Solubilization was achieved by mixing the cellular 
extract in this buffer for one hour. To remove anionic impurities, 1 g of DE52 anionic 
exchange cellulose resin (Whatman, Maidstone, Kent, UK) equilibrated with Buffer A 
(TBS, 0.5% LS, 6 M urea), was added to the total extract and mixed for another hour. 
The DE52 resin was then removed by centrifugation at 8000 rpm for 15 min at 15°C. 
The supernatant was decanted and imidazole (5M stock) was added to 10 mM. 
Approximately 5 mL nickel-charged resin (see below) equilibrated with Buffer A + 10 mM 
imidazole was then added to the supernatant and this mixture was then gently shaken 
for an hour. The mixing of resin directly into the cell extract was done instead of 
applying the extract to a column due to the increased thickness of the extract that is a 
result from this new procedure. !
! The nickel-charged resin with SN-SP-B fusion protein bound is removed from the 
rest of the extract by centrifugation at 8000 rpm for 15 minutes at 15°C. The 
supernatant is discarded and the resin is resuspended in a small amount of Buffer A + 
10 mM imidazole at 20°C and applied to a column. This is followed by a washing of the 
column using 20 mL Buffer B (TBS, 0.2% LS, 6 M urea) + 10 mM imidazole. The fusion 
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protein is then eluted using a step-wise imidazole gradient with the application of Buffer 
B + 25 mM imidazole followed by 25, 50, 100, 200, and 300 mM imidazole (10 mL 
each). The elution was collected as approximately 1.5 mL fractions using gravity. The 
location of the fusion protein (and any other bound expression products) was 
determined using OD280 of the fractions followed by SDS PAGE with an 18% 
polyacrylamide gel. The presence of SP-B was confirmed using Western blot analysis 
with an anti-SP-B antibody. SP-B was confirmed in both 8 kDa and 26 kDa bands in the 
SDS PAGE gel. Fractions containing both samples were separately pooled and dialyzed 
overnight against water using 1000 Da dialysis tubing (Thermo Scientific, NC, USA) for 
the 8 kDa sample and 12-14 kDa dialysis tubing (Sigma-Aldrich, St. Louis, MO, USA) 
for the 26 kDa sample. The samples were lyophilized by transferring them into freeze-
drying flasks (Labconco, Kansas City, MO, USA) and flash freezing them using liquid 
nitrogen. The flasks are then hooked up to a freeze drier overnight or until all the ice 
had evaporated leaving a dry protein powder. Both of the dried protein samples were 
then stored at 4°C.!
!
2.6 Nickel-Bound Immobilized Metal Ion Affinity Chromatograhphy (IMAC)"
! To prepare the resin (IMAC Separose 6 Fast Flow, GE Healthcare Life Sciences, 
Piscataway, NL, USA), it was poured into a small column (1 cm diameter) and the fluid 
allowed to flow through. Ni ions in the form of nickel (II) sulfate (1/2 column volume of 
0.1 M NiSO4) was added to the resin which was then washed with excess deionized 
water and stored until ready for use.  Before use, the column is equilibrated with one 
 33
column volume starting buffer. After use, the column is re-equilibrated with two column 
volumes starting buffer and stored at room temperature. !
!
2.7 Cyanogen Bromide Digestion"
! The lyophilized protein samples were dissolved in 2 mL, 70% formic acid. An 
excess of cyanogen bromide was then added and the reaction was allowed to take 
place overnight at room temperature in the dark. Cyanogen bromide is a dangerous 
compound to work with so precautions must be taken such as wearing the proper safety 
equipment (ie. lab coat, gloves, and eye protection). Handling of the cyanogen bromide 
and the reaction itself must be completed in a fume hood. Accurate measurements 
cannot be obtained inside a fume hood so an obvious excess of cyanogen bromide was 
dissolved in the solution (ie. a small amount on the end of a spatula). The following day, 
28 mL deionized water was added to the reaction mixture to create a 1:15 dilution. The 
sample was lyophilized and the resulting dry protein sample was stored at 4°C 84.!
!
2.8 Enrichment of SP-B"
! Enriching the modified SP-B requires separating it from the SN fragments 
produced during cyanogen bromide digestion as well as any undigested fusions. The 
enrichment was a challenging endeavour which involved attempts of several enrichment 
techniques. All of the isolation work described below was done with the 26 kDa samples 
obtained from the expression of SN-Δ7NTΔM-SP-B-6His.!
!
!
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2.8.1 Organic Extraction"
! The first attempt to separate SP-B from the impurities was through the use of an 
organic extraction similar to that used to isolate recombinant SP-C 76. The lyophilized 
cyanogen bromide digest was resuspended in 2 mL deionized water with 0.5% LS. To 
the suspension, one volume of methanol and one volume of chloroform were added. 
This mixture was vortexed and incubated at 37°C for 30 minutes, after which another 
volume of chloroform and one volume of deionized water were added. After vortexing, 
the layers were separated by centrifugation at 1500 rpm for 5 minutes at 15°C, during 
which an unexpected insoluble layer formed between the organic and aqueous phases. 
The bottom, organic layer was carefully removed and kept in a separate flask. To the 
remaining aqueous and insoluble phases, another two volumes of chloroform was 
added. The mixture was once again vortexed and centrifuged as before with the bottom, 
organic layer removed and pooled with the first organic sample. The insoluble 
precipitate was removed from the aqueous phase through centrifugation in a 
microcentrifuge. The aqueous layer was then decanted and lyophilized while the 
organic phase was dried under a stream of nitrogen. The protein content of all three 
phases: organic, insoluble, and aqueous were analyzed through SDS PAGE using an 
18% polyacrylamide gel. !
!
2.8.2 High Performance Liquid Chromatography (HPLC)"
! The next attempt at enriching the SP-B was through HPLC. A freeze dried, 
cyanogen bromide digested SN-SP-B sample was mixed into a 1 mL solution of 80% 
acetonitrile, 20% HPLC grade water, and 0.1% trifluoroacetic acid (TFA). The solution 
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was mixed gently in an attempt to dissolve as much protein as possible. After mixing, 
the cloudy solution was passed through a 25 mm syringe filter with a 1 μm glass fiber 
membrane (Pall Life Sciences, Ann Arbor, MI, USA). The resulting clear solution was 
then applied to a reverse-phase DYNAMAX C8 HPLC column (Varian Inc., St. Laurent, 
QC, Canada) at 20°C and eluted with an acetonitrile gradient (20% - 100%) pumped 
through the column at a rate of 15 mL per minute and collected as approximately 5 mL 
fractions. Fractions containing protein were identified using an OD280 profile and each 
separate elution was pooled. Each eluted sample was analyzed by SDS PAGE with an 
18 % polyacrylamide gel to determine the location of SP-B. !
!
2.8.3 Cationic Exchange Chromatography"
! A freeze dried, cyanogen bromide digested SN-SP-B sample was first dissolved 
in 6 M urea to break up the aggregates and allow the protein to solubilize. To this 
solution, PC was added to a 5:1 lipid to protein ratio and incubated for 10 minutes at 
39°C followed by vortexing for one minute. This incubation/vortexing was repeated for a 
further 90 minutes after which the mixture was dialyzed against 4 L water overnight. 100 
mg CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate) detergent 
(dissolved in 200 μL deionized water) was then added to the mixture and gently stirred 
until the solution was clear. !
! A starting buffer of 50 mM phosphate (5.74 g/L Na2HPO4, 1.2 g/L KH2PO4), 10 
mM CHAPS, and 0.025 M NaCl, pH = 7 was prepared. This solution was used to dilute 
the protein/lipid sample to 10 mL and equilibrate a HiTrap cationic exchange column 
(GE Healthcare Life Sciences, Piscataway, NL, USA). The 10 mL of sample was applied 
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to the column at 20°C and the protein was eluted with a step-wise salt gradient using 
the same solution as the starting buffer except with increasing NaCl concentrations 
(0.025, 0.1, 0.25, 0.5, 0.75, and 1 M). 10 mL of each step was used and passed through 
the column using a peristaltic pump at about 2 mL per minute. The elution was collected 
in approximately 1 mL fractions and analyzed by OD280 and SDS PAGE with a 18% 
polyacrylamide gel. After use, the HiTrap cationic exchange column was washed with 
excess deionized water.!
!
2.8.4 Sephadex LH20 Enrichment of SP-B from Cyanogen Bromide Digest"
! After dialysis, the products of the cyanogen bromide digest tend to heavily 
aggregate making them very insoluble. In an effort to force these aggregates into an 
organic solution required for certain separation techniques, a new solubilization 
procedure was tried. The digest was first dissolved in 5 mL, 6 M urea and DPPC was 
added in a 5:1 lipid to protein ratio. The mixture was incubated for 10 minutes at 39°C 
then vortexed for one minute, a cycle which was repeated over the course of 90 minutes 
to create DPPC vesicles. The mixture was then dialyzed against 4 L deionized water 
overnight and lyophilized. A 2:1 mixture of chloroform and methanol was added to the 
protein/lipid dried powder until it was successfully dissolved (solution turned clear), 
approximately 2 mL solvent.!
! Once this solution was created, LH20 chromatography was used in an effort to 
separate the SP-B from the impurities. A solvent resistant chromatography column (2.5 
x 100 cm) was packed with Sephadex LH-20 resin (GE Healthcare Life Sciences, 
Piscataway, NL, USA). The column was equilibrated using 2:1 chloroform:methanol and 
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the 2 mL sample was applied at 20°C. The lipids and protein were eluted from the 
column with excess 2:1 chloroform:methanol and collected as 1.5 mL fractions without 
the use of a pump. The fractions were analyzed at OD240 and OD280 and those 
suspected of containing protein were dried under nitrogen gas and inspected by SDS 
PAGE on an 18% polyacrylamide gel. The presence of SP-B was confirmed using 
Western blotting with an anti-SP-B antibody and those fractions containing SP-B were 
pooled and stored at -20°C. After use, the LH20 column was washed with 2:1 
chloroform:methanol.!
!
2.9 Functional Studies of Recombinant SP-B"
" With a partially enriched recombinant SP-B, functional studies were undertaken 
to compare the expressed SP-B with native SP-B obtained from porcine lung lavages. 
These functional studies include membrane leakage and lipid mixing assays as well as 
surface activity studies with a captive bubble surfactometer (CBS). All of these studies 
were conducted in the Jesus Perez-Gil lab at the Universtidad Complutense de Madrid 
(Madrid, Spain).!
!
2.9.1 Membrane Leakage Assay"
! This experiment required the production of large unilamellar vesicles (LUVs) with 
encapsulated fluorophores. The LUVs were made up of dipalmitoylphosphatidylcholine 
(DPPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), and 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphoglycerol (POPG) in a 50:25:15 ratio. 10 mg/mL of this lipid 
mixture was added to a buffer of 5 mM Tris, 150 mM NaCl at pH = 7. The fluorophore 
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ANTS (8-aminonaphthalene-l,3,6-trisulfonic acid) and its quencher, DPX (p-xylene-bis-
N-pyrimidinum bromide), were also added (12.5 mM and 45 mM respectively). 
Multilamellar vesicles (MLVs) were formed by alternating shaking and resting periods at 
45°C for 90 minutes (ie. one minute shaking followed by 10 minutes rest). From these 
MLVs, LUVs were formed with five freeze-thaw cycles in liquid nitrogen. To ensure a 
consistent vesicle size as well as remove any remaining MLVs, the mixture was forced 
through an extruder with a 100 nm pore membrane. Because the LUVs were formed in 
a solution containing the fluorophores ANTS and DPX, these fluorophores will have 
been encapsulated inside the LUVs. To remove the free fluorophores not encapsulated, 
which would interfere with the leakage assay, the mixture was applied to a Sephadex 
G100 (GE Healthcare Life Sciences, Piscataway, NL, USA) gel filtration column (1.5 x 
15 cm). The LUVs passed freely through the column while the free fluorophores were 
retained and eluted with excess buffer (5mM Tris, 150 mM NaCl, pH = 7) and collected 
in fractions. The lipid and fluorophores were tracked using OD400 (lipids), OD353 (ANTS), 
and OD259 (DPX). The lipid content of fractions containing LUVs were quantified using a 
phosphorous assay (see below) and used for the leakage assay.!
! The native SP-B was provided by the Jesus Perez-Gil lab while the recombinant 
SP-B was produced as described above. Both samples were stored in a solvent of 2:1 
chloroform and methanol. As chloroform interferes with the fluorescence 
measurements, it had to be removed in favour of a methanol only solvent. Samples of 
both SP-Bs were slowly dried under nitrogen gas with the addition of excess methanol 
to prevent complete drying and protein aggregation. Chloroform is more volatile than 
methanol so will dry off first leaving the protein is a solution of methanol. Both SP-B 
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solutions, whose concentrations had previously been determined using amino acid 
analysis, were diluted to a final concentration of 60 μM.!
! The LUVs were diluted to a lipid concentration of 30 μM and 300 μL aliquots of 
this solution were added to cuvettes to analyze with the fluorimeter (SLM-Aminco AB2, 
Urbana, IL). The samples were excited at 353 nm (the excitation wavelength of ANTS) 
and emission at 520 nm (the emission wavelength of ANTS) was recorded. The 
emission at 520 nm of the LUVs alone was taken to be the minimal emission or leakage 
(F0). The maximum leakage (F100) was determined by adding 5 μL of the detergent 
Triton X-100 and recording the emission at 520 nm. Triton X-100 will dissolve the 
membranes of the LUVs allowing for total leakage. !
! The leakage experiments were performed for both the native and recombinant 
SP-B by adding 5 μL of the 60 μM SP-B solutions for a final concentration of 1 μM. 
Emission at 520 nm was recorded over a 10 minute period with the final emission 
recorded as Fp. This was repeated by adding another 5 μL SP-B to the cuvette to 
produce a 2 μM experiment, followed by a 3 μM and 4 μM experiment. The percent 
leakage (%L) was calculated using the formula:!
!
%L = 100 (Fp - F0) / (F100 - F0)!
!
where Fp is final emission, F100 is maximum emission, and F0 is initial emission. To 
ensure the methanol of the SP-B samples was not interfering with the experiment, 20 μL 
of methanol alone was added to another 300 μL LUV sample and excited at 353 nm. No 
significant change in the emission at 520 nm was observed.!
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2.9.1.1 Phosphorous Assay"
! To determine the concentration of phosphorous containing lipids in several of the 
samples used during the functional experiments, a phosphorous assay was used. 
Standards were first made using different amounts of KH2PO4 (0.0037, 0.015, 0.026, 
0.037, 0.092, 0.147 μmol). Experimental tubes containing different amounts of the 
unknown lipid solutions were also prepared. All tubes were dried down in a 250°C sand 
bath. 450 μL perchloric acid was added to each tube which were further incubated in the 
sand bath for 30 minutes at 250°C. 3.5 mL deionized water, 500 μL ammonium 
molybdate (2.5%), and 500 μL ascorbic acid (10%) were added to each tube and 
vortexed. The tubes were incubated in a 100°C water bath for 7 minutes after which the 
absorbance at 820 nm was determined for each tube. From this, a standard curve was 
generated. Using this curve and the absorbance of the experimental tubes, the lipid 
concentrations of the unknown samples were calculated.!
!
2.9.2 Lipid Mixing!
! LUVs also had to be prepared for the lipid mixing experiments. This time, 
however, instead of encapsulated fluorophores, these LUVs would have fluorophores 
attached directly to the membrane and make use of the fluorescence resonance energy 
transfer (FRET) technique . The fluorophores in this case are the FRET donor, NBD (7-
nitro-4-benzofurazanyl), and the FRET acceptor, Rhodamine. These fluorophores are 
attached to phosphatidylethanolamine (PE) which will allow them to be incorporated into 
the vesicular membrane. Both labelled and unlabelled LUVs were formed, made as 
before at a concentration of 50 μg/mL DPPC/POPC/POPG in a 50:25:15 ratio. These 
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labelled LUVs were made with NBD-PE and Rhodamine-PE (0.4 μM each) but were not 
subjected to chromatography and phosphorous assay steps. The same SP-B samples 
from the leakage experiments were also used. !
! For the lipid mixing experiments, the LUVs were mixed together in a 1:9 ratio of 
labelled to unlabelled, maintaining a total lipid concentration of 50 μg/mL. 300 μL of the 
mixture of vesicles was injected into a cuvette and placed into a fluorimeter at 37°C. 
The sample was excited at 450 nm (excitation wavelength of NBD) and the emission 
spectra from 500-650 nm was recorded to show FRET activity with no lipid mixing. This 
was followed with the addition of 5 μL of the 60 μM native SP-B sample for a final SP-B 
concentration of 1μM. The solution was mixed and allowed to rest for 5 minutes at 
which time another spectra from 500-650 nm was recorded. This was followed by the 
addition of more native SP-B to achieve 2, 3, and 4 μM SP-B concentrations. These 
experiments were repeated with the recombinant SP-B. To ensure the methanol of the 
SP-B solutions had no adverse effect on the experiments, a final trial was attempted 
with the injection of 20 μL methanol in 300 μL of the 50 μg/mL LUV sample. !
!
2.9.3 Captive Bubble Surfactometer (CBS)"
! A captive bubble surfactometer (CBS) is a device used to mimic the environment 
inside an alveolus. It contains a chamber in which a small bubble can be created 
floating above a Tris buffered solution (5 mM Tris, 150 mM NaCl, 10% sucrose, pH = 7). 
The bubble can be observed with a camera and loaded into computer software which 
can calculate the surface tension of the bubble through its size and shape. The buffer 
contains sucrose to increase its density, allowing injected samples to float upwards to 
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the air-water interface of the bubble. The samples are injected through a small opening 
in the bottom of the chamber using a micro-syringe. The whole chamber is surrounded 
by a temperature-controlled water jacket which keeps the temperature of the system 
constant (37°C in the case of these experiments). In this thesis, three experiments are 
performed with the CBS: initial absorption, post expansion absorption, and dynamic 
simulation.!
! For these experiments, MLVs were formed in the presence of both native SP-B 
and recombinant SP-B. These MLVs were made of DPPC/POPC/POPG in a 50:25:10 
ratio. The appropriate amount of SP-B was added to a solution of 25 mg/mL lipids in a 
Tris buffer (5 mM Tris, 150 mM NaCl) and the MLVs were prepared through alternating 
periods of shaking and rest at 45°C over the course of 90 minutes. For native SP-B, 1% 
and 2% (of total lipid mass) solutions were prepared while for recombinant SP-B, 5% 
and 10% solutions were used. A lipid only control sample containing just the 25 mg/mL 
lipids was also prepared for the upcoming experiments. !
!
2.9.3.1 Initial Absorption (IA)"
!  With initial absorption (IA) experiments, a bubble is first created in the chamber. 
Then the sample is injected and allowed to spread across the air-water interface. The 
change in surface tension this causes is recorded over the course of 5 minutes. This 
experiment was done for the lipids alone, native SP-B (1% and 2%), and recombinant 
SP-B (5% and 10%) samples. For the first trial, the samples were injected below the 
bubble and allowed to float upwards toward the air-water interface of the bubble. When 
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this proved problematic for the recombinant SP-B samples, the experiments were 
repeated by injecting the samples with the injector physically touching the bubble.!
!
2.9.3.2 Post Expansion Absorption (PEA)"
! Post expansion absorption (PEA) experiments use the same bubbles described 
in the IA experiments above. After the IA experiment is completed, the chamber is 
sealed and expanded, creating a negative pressure. This causes the bubble to expand 
forcing the sample to spread across the increased surface area. The surface tension of 
the air-water interface was recorded over 5 minutes. These experiments were also 
completed with both injection procedures (touching the bubble and not touching the 
bubble).!
!
2.9.3.3 Dynamic Simulations"
! After the PEA experiments, dynamic simulations were carried out. These 
experiments most accurately mimic the activity of an alveolus. The chamber remains 
sealed and is expanded and contracted which also causes this bubble to expand and 
contact. This is done at a rate of 20 cycles/minute which is the approximate breathing 
rate in humans. The surface tension changes in the air-water interface is recorded in the 
1st, 10th, and 20th cycles. These dynamic simulation experiments were again 
completed with both injection procedures (touching the bubble and not touching the 
bubble).!
!
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!
3.! Results!
!
3.1 SN-Δ7NTΔM-SP-B-6His Expression Level and Cellular Location"
! After the plasmid was transfected into the C43 E. coli cells, it had to be 
determined if the fusion protein will express and identify which cellular fraction it is 
located in. This is important to know as it indicates which fractions should be used for 
the isolation procedure, and which should be discarded. Fusion proteins are typically 
designed to allow them to locate to the soluble fraction, however the very hydrophobic 
SP-B part could result in the fusion being directed into the membrane fraction and/or 
into insoluble inclusion bodies. The small one litre expression described in the Materials 
and Methods was split into three fractions highlighted in Table 3 and separated into 
soluble, membrane and inclusion body fractions as follows. Lauroyl sarcosine (LS) was 
used to solubilize the membrane fraction and urea was used to solubilize the inclusion 
bodies (insoluble). !
!
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Table 3: The different samples of cellular extracts of a small scale expression of SN-
Δ7NTΔM-SP-B-6His and the solvent conditions of each sample. This was carried out in 
order to determine which sample (ie. fraction) contains the largest quantities of SN-SP-
B fusion protein.!
!
!
!  
Sample Cellular Extract Fraction Solvent Conditions
1 soluble TBS
2 soluble + membrane TBS + 0.5% LS
3 soluble + membrane + 
insoluble
TBS + 0.5% LS + 6M urea
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! After running the fractions on a nickel bound IMAC column, portions of each were 
analyzed by SDS PAGE, shown in Figure 5. In each fraction, bands appeared around 
26 kDa which is the approximate size of the expressed fusion protein. These bands 
were thus assumed to be the fusion protein indicating SN-Δ7NTΔM-SP-B-6His does 
express at detectable levels. This assumption would later be verified using Western 
blotting with an anti-SP-B antibody (Figure 8). Protein expression was detected in all 
fractions and the relative amounts in each fraction were determined by observing the 
size and amount of staining. The band from the soluble + membrane + insoluble fraction 
was the largest/darkest indicating that this fraction contained the most fusion protein. As 
a result, all future purifications of the SN-SP-B fusion were done using this fraction.!
!
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!
Figure 5: An 18% polyacrylamide gel showing the SDS PAGE of the different cellular 
extract fractions of a small scale expression of SN-Δ7NTΔM-SP-B-6His. Stained with 
Coomassie Brilliant Blue (CBB) R250. !
!
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3.2 Large Scale Expression of SN-Δ7NTΔM-SP-B-6His"
! Once I determined most of the protein was in the insoluble fraction, large scale (6 
L) expressions were prepared. These cells were lysed and solubilized with the TBS, 
0.5% LS, and 6 M urea, and the fusion protein (with 6xHis tag) was enriched using 
nickel-bound IMAC. After the lysate was loaded onto the column, it was washed with 
buffer containing 25 mM imidazole and then eluted in steps of 50, 100, 200, and finally 
300 mM imidazole. Each step lasted about 10 mL or approximately 7-8 fractions. The 
elution profile was monitored by measuring the absorbance at 280nm (Figure 6). Peaks 
at fractions 4-9 (Peak A) and 10-16 (Peak B) can be observed. Further increases in 
absorbance at 280 nm can be seen after these peaks, however this is likely due to the 
increased imidazole concentration and not the presence of protein. !
! Figure 7 shows select fractions which were run on an SDS PAGE using an 18% 
polyacrylamide gel and CBB R250 staining. Two major bands appear, one from 
fractions 4, 6, and 8 with another from fractions 10, 12, and 14 with some crossover 
between the two. The first band is approximately 8 kDa while the second is about 26 
kDa. These bands correspond to peaks A and B respectively. !
! A Western blot was also done on these fractions (Figure 8) to determine the 
identity of the bands. This Western blot was done using an anti-SP-B antibody. While 
the appearance is faint, SP-B is successfully detected in both fractions 6 and 12. These 
positive bands correspond to the strongest bands (1 and 2) from the SDS PAGE in 
Figure 7. It is unclear why there are two bands both positive for SP-B. !
! Theoretically, the SN-Δ7NTΔM-SP-B-6His plasmid construct should only produce 
a fusion protein of 26 kDa in mass. The second band from Figure 7 (ie. Peak B from 
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Figure 6) most closely resembles the expected size for the fusion. However, the first 
band from Figure 7, (ie. Peak A from Figure 6) at an apparent molecular mass of 8 kDa, 
is something other than the fusion. One possibility, that will be elaborated on in the 
discussion, is that Peak A corresponds to SP-B and a carboxy-terminal histidine tag that 
had been expressed without the SN fusion.!
! The fractions containing the fusion protein were pooled together and lyophilized 
in preparation for cyanogen bromide cleavage. The amount of undigested protein 
isolated in this step averaged about 10 mg per litre of culture. Fractions containing the 
SP-B expressed alone were also separately pooled and lyophilized. The protein isolated 
here averaged about 5 mg per litre of culture.!
!
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!
Figure 6: Elution profile from the nickel-bound IMAC column used to isolate the SN-SP-
B fusion protein from the cellular extract. Protein was detected using an absorbance at 
280 nm. Peaks A and B represent the two areas positive for protein. The subsequent 
peaks are the result of interference of the increased concentration of imidazole. 
Fractions 4-9 (Peak A) and fractions 10-16 (Peak B) were separately pooled as SP-B 
positive samples.!
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!
Figure 7: A precast 16.5% polyacrylamide gel showing the SDS PAGE of elution 
fractions from the nickel-bound IMAC column used to isolate the SN-SP-B fusion protein 
from the cellular extract. The fraction numbers are displayed across the top with the 
final lane containing a protein size reference marker. The size of each marker in kDa is 
displayed down the right of the gel. Stained with Coomassie Brilliant Blue (CBB) R250, !
two main protein bands were observed.!
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!
Figure 8: Western blot analysis of elution fractions from the nickel-bound IMAC column 
used to isolate the SN-SP-B fusion protein from the cellular extract, using the same 
sample from Figure 7. The fraction numbers are displayed across the top with the final 
lane containing a protein size reference marker. The size of each marker in kDa is 
displayed down the right of the membrane. The circled bands represent the antigen-
antibody binding of the anti-SP-B antibody. The dark bands at the top are markers used 
to identify the lanes.  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3.3 Cyanogen Bromide Cleavage"
! The lyophilized SN-SP-B fusion protein was then cleaved using a cyanogen 
bromide digest, as described in the Materials and Methods. As seen in Figure 4, there 
are cyanogen bromide cleavage sites (ie. methionine residues) positioned between the 
SN and SP-B as well as between the SP-B and histidine tag.  There are also four 
methionine located throughout the SN sequence which would also result in the SN 
protein being digested into several pieces. This cleavage reaction will thus result in a 
recombinant SP-B that is no longer attached to anything. While the cyanogen bromide 
reaction is very efficient, there is the possibility of incomplete digestion. In other words, 
there could still be some SP-B that remains attached to SN fragments that would add 
another complication to the enrichment of SP-B. Cyanogen bromide will not cleave after 
a methionine that has been oxidized. Therefore, the presence of oxidized methane 
could present another source of incomplete digestion. Ideally, this enrichment would 
lead to a SP-B sample that is relatively pure of SN fragments, the histidine tag, and 
incomplete digests, however, this would prove to be very difficult to achieve. !
! Figure 9 shows a Western immunoblot of the SN-SP-B fusion sample before and 
after cleavage using an anti-SP-B antibody. Before cleavage, two positive SP-B bands 
appear, one identified as the fusion at about 26 kDa (with respect to the protein marker) 
and another below this. The lower band is approximately 8 kDa (with respect to the 
peptide marker) and is in all likelihood the SP-B that is expressed alone. As observed in 
Figure 7 there is always some crossover between the two expressed SP-Bs and thus 
contamination of the SN-SP-B with SP-B alone in inevitable. Because the end goal is to 
achieve an enriched sample of SP-B alone, this contamination is irrelevant. !
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! After the cyanogen bromide cleavage, the 26 kDa band entirely disappears and 
the lower 8 kDa band’s signal becomes stronger. This indicates that the cleavage was a 
success leading to an increase in SP-B alone. However, two weaker SP-B positive 
bands can be observed above the 8 kBa band but below the original 26 kDa band. 
These other bands likely arise from incomplete cleavage and thus, along with the SN 
fragments and histidine tag, must be removed during enrichment. Also worth noting is 
the presence of SP-B positive bands above 26 kDa. This is likely due to the 
oligomerization of SP-B which has been observed previously.!
!
!
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Figure 9: Western blot analysis of the isolated SN-SP-B fusion before and after 
cyanogen bromide cleavage. The outside lanes contain size reference markers. The 
sizes of each marker in kDa are displayed down the sides of the image. The bands 
represent the antigen-antibody binding of the anti-SP-B antibody. All lanes are from the 
same Western blot. The darker colour of the peptide marker lane is due to the middle 
lanes being removed from this image. Other bands are likely due to unspecific binding 
of the antibodies.!
Before 
Cleavage
After
Cleavage
25
20
15
150
100
75
50
37 26.6
17.0
14.4
6.5
3.5
Protein
Marker
Peptide
Marker
Fusion
SP-B Alone
 56
3.4 Enrichment of Recombinant SP-B"
!
3.4.1 Organic Extraction"
! After the successful cleavage of the fusion protein, the next step was to attempt 
to isolate the SP-B from other cleavage products. Because SP-B is very hydrophobic 
and the SN fragments and histidine tag hydrophilic the most obvious enrichment 
method to use would be organic extraction. The completion of an organic extraction of 
the cyanogen bromide digest should, in theory, result in the SP-B being dissolved in 
organic solvent with the other impurities dissolved in a separate aqueous layer. Where 
the incomplete digests would appear is harder to predict as they have both hydrophobic 
and hydrophilic parts. If they were to appear in the organic solvent with the SP-B they 
could possibly be removed through a subsequent chromatography step. !
! The organic extraction carried out on the cyanogen bromide cleavage products 
yielded an unexpected result (see Figure 10A). An insoluble precipitate formed between 
the organic and aqueous phases. Samples from the organic, inorganic, and aqueous 
phases were analyzed using SDS PAGE (see Figure 10B). Nothing appears to have 
dissolved in the organic phase, while protein is present in both the insoluble and 
aqueous phases. This is likely the result of aggregation of the SP-B. Due to its very 
hydrophobic nature, SP-B has a tendency to stick to itself and other proteins which 
makes work with this protein extraordinarily difficult. SP-B is most likely the band just 
above 6.5 kDa and as can be seen in the gel, neither the insoluble nor inorganic phases 
offered any significant enrichment. As a result, the use of this method was discarded.!
!
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Figure 10: Organic extraction of cyanogen bromide digest. a) A schematic of what 
results in a glass tube when an organic extract is performed on the cyanogen bromide 
cleavage products of the SN-SP-B fusion protein. b) A precast 16.5% polyacrylamide 
gel showing the SDS PAGE analysis of the three portions of the organic extraction seen 
in Figure 7A. The final lane contains a size reference marker with the size of each 
marker in kDa displayed down the right side of the gel. The gel is stained with CBB-
R250. The large smear in the organic lane is likely due to the presence of lipids in the 
sample.!
!
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3.4.2 High Performance Liquid Chromatography (HPLC)"
! The next method that was attempted to separate SP-B from the impurities was 
HPLC, using a C8 column which has 8 carbon chains attached to resin. The use of such 
a column is called reverse phase chromatography and allows for separation of proteins 
based on hydrophobicity. Hydrophobic proteins (in this case SP-B) will stick to the resin 
while the rest will flow through the column. The SP-B was eluted using an organic 
solvent (acetonitrile) gradient. The C8 column was used as opposed to the much more 
common C18 because SP-B is so hydrophobic it will bind strongly to the C18 resin and 
not elute. The elution was collected in fractions and a profile was generated (see Figure 
11). Each peak was pooled and samples from each were analyzed through SDS PAGE 
(see Figure 12). !
! Almost nothing showed up on the gel and the dried fractions yielded little to no 
protein. This is likely the result of the filtration of the sample before application to the 
column. After the protein was mixed in the 80% acetonitrile solution, the sample was 
cloudy. However, after filtration, the sample became clear and colourless. With the 
result from the organic extraction in mind, it is likely that the SP-B did not dissolve in the 
acetonitrile/water mixture and as a result, was lost during filtration 85. Like organic 
extraction, HPLC did not help enrich SP-B and therefore, a different method was 
approached.!
!
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Figure 11: Elution profile of fraction taken from the HPLC of the cyanogen bromide 
digest. Protein was detected using an absorbance of 280 nm. The peaks analyzed with 
SDS PAGE are labelled A-J.!
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Figure 12: Precast 16.5% polyacrylamide gels showing the SDS PAGE of various 
elution fractions from the HPLC of the cyanogen bromide digestion products of the SN-
SP-B fusion. The different fractions are displayed across the top and represent the 
same fraction from the elution profile in Figure 11. The first lane contains a size 
reference marker with the size of each marker in kDa displayed down the left side of the 
gel. The gels were stained with CBB-R250.!
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3.4.3 Cationic Exchange Chromatography"
! The next attempt at enriching the SP-B was through the use of cationic exchange 
chromatography. This chromatographic method utilizes resin that has a negative 
charge. Positively charged molecules, like SP-B (+7 at neutral pH), should bind to the 
resin allowing others to pass through. The bound cations are then eluted using a salt 
gradient. While some SN fragments will also be positively charged, they are less 
positive than SP-B and therefore should elute from the column earlier. The detergent 
CHAPS was used to try to dissolve SP-B in an aqueous buffer and unlike HPLC, the 
sample did not need to be filtered before applying to the column, therefore loss of 
sample should not be an issue. The elution was collected as fractions and a profile was 
generated (see Figure 13). Select fractions were also analyzed using SDS PAGE (see 
Figure 14).!
! From the profile in Figure 10, you can see a high absorbance from the first 10 
fractions. Analysis of fraction 3 (Figure 14) shows that this large peak contained most of 
the CHAPS detergent (CHAPS appears as a large smear on SDS PAGE) as well as 
most of the proteins (the two large distorted bands above the smear) indicating that very 
little of the protein had bound to the column. The little protein that did bind eluted 
gradually with no separation, which can be seen in the other lanes of the gel in Figure 
14. Aggregation of the protein in the digested sample could possibly lead to the 
blockage of the charged portions of SP-B and therefore rendering it unable to bind to 
the anionic resin. Once again, the failure of cationic exchange chromatography to 
improve enrichment has led me to look elsewhere. !
!
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Figure 13: Elution profile from the cationic exchange chromatography of the cyanogen 
bromide digestion products of the SN-SP-B fusion protein. Protein was detected using 
an absorbance at 280 nm. The inset contains an expanded look at fractions 10-130. !
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Figure 14: An 18% polyacrylamide gel showing the SDS PAGE of various elution 
fractions from the cationic exchange chromatography of the cyanogen bromide 
digestion products of the SN-SP-B fusion. The different fractions are displayed across 
the top and represent the same fractions from the elution profile in Figure 10. The first 
lane contains a size reference marker with the size of each marker in kDa displayed 
down the left side of the gel. The second lane (Fraction 3) contains a large smear 
caused by the CHAPS. Despite this, thick distorted protein bands can be observed 
above the smear. The gel was stained with silver staining.!
!
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3.4.4 Sephadex LH20"
! What was obvious at this point was that the SP-B and other digestion products 
were very insoluble. The likely culprit of this insolubility is protein aggregation. I have 
found that a high concentration of urea is capable of breaking up these protein 
aggregates. While the denaturing property of urea makes this possible, it is also the 
denaturing effect that makes it undesirable for any structural or functional work which is 
the ultimate goal of this work. A resolution to this problem was found using a new 
solubilization procedure with DPPC vesicles that is described in detail in the Materials 
and Methods. This procedure involved first dissolving the protein aggregate in high 
molar urea and then adding the DPPC vesicles. The hydrophobic SP-B should bind to 
these vesicles and after a period of dialysis the urea is removed leaving only the SP-B 
bound vesicles. Once lyophilized, this protein-lipid mixture dissolved readily in a organic 
solvent of 1:1 chloroform and methanol. Once dissolved in this solvent, I was able to 
apply the sample to a chromatography column containing LH20 resin which is a size 
exclusion column able to withstand the harsh conditions of organic solvent. !
! The first attempt at an LH20 chromatography was made using a sample of the 
SP-B expressed alone (ie. the 8 kDa band from Peak A in Figure 6). This sample was 
digested with cyanogen bromide (to remove the carboxy-terminal histidine tag) and 
solubilized using the urea/DPPC vesicle method. The LH20 profile featured in Figure 15 
shows at least four major peaks which contain protein and lipids. Samples from these 
peaks were analyzed using SDS PAGE and Western blot (Figure 16). There is one 
visible band present from fraction 75 and tested positive for SP-B using anti-SP-B in the 
Western blot. While this is a very encouraging result, low yields of the SP-B expressed 
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alone resulted in too little enriched protein to do any meaningful research with. Because 
of the inability to increase this yield, the same method was applied to the SN-SP-B 
fusion digest which was expressed in much larger quantity.!
! The resulting profile of the LH20 chromatography with the fusion digest can be 
seen in Figure 17. As before, select fractions were analyzed with SDS PAGE and 
Western blotting (Figures 18 and 19) using duplicate gels. A thick band appears from 
fraction 77 in the gel in Figure 18. This was confirmed to be SP-B in the Western blot 
with anti-SP-B in Figure 19. The gel appears inconsistent with the chromatography 
profile in that the protein was present at a very small absorbance (about 0.05) whereas 
the large peaks centred around fractions 111 and 200 contained yielded no protein on 
the SDS PAGE/Western blot. These large peaks could be from other molecules present 
in the elution.!
! Once again, the enrichment of SP-B from the LH20 column was achieved and 
this time in larger quantities than the SP-B that had expressed by itself. This larger yield 
came at a price, however, as other bands present from fraction 77 (Figure 18) indicate 
the SP-B is not completely enriched. While this is an impediment to structural studies 
through solution NMR, it should be pure enough to undergo functional studies. Fractions 
72-83 were pooled and dried. The total rSP-B isolated through this process was 
determined to be approximately 150 μg. This value was measured using amino acid 
analysis. Therefore the total yield of enriched rSP-B was 25 μg/L of culture.!
!
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Figure 15: Elution profile from the LH20 size exclusion chromatography of the cyanogen 
bromide digestion products of the SP-B-expressed-alone sample. Protein was detected 
using absorbance at 240 and 280 nm. The fractions contained approximately 1.5 mL.  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!!
Figure 16: Analysis of Sephadex LH20 chromatographed SP-B-expressed-alone by 
SDS PAGE and Western blotting. A) A precast 16.5% polyacrylamide gel showing the 
SDS PAGE of various elution fractions from the LH20 size exclusion chromatography of 
the cyanogen bromide digestion products of the SP-B expressed alone sample. The gel 
was stained with CBB R250. B) A Western blot analysis of various elution fractions from 
the LH20 size exclusion chromatography of the cyanogen bromide digestion products of 
the SP-B expressed alone sample. The bands represent the antigen-antibody binding of 
the anti-SP-B antibody. The different fractions in both figures are displayed across the 
top and represent the same fractions from the elution profile in Figure 15. The left-hand 
lanes in each contain a size reference marker with the size of each marker in kDa. 
These were created using duplicate gels.!
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Figure 17: Elution profile from the LH20 size exclusion chromatography of the cyanogen 
bromide digestion products of the SN-SP-B fusion protein. Protein was detected using 
absorbance at 240 and 280 nm. The fractions contained approximately 1.5 mL. 
Fractions 72-83 were pooled.!
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Figure 18: A precast 16.5% polyacrylamide gel showing the SDS PAGE of various 
elution fractions from the LH20 size exclusion chromatography of the cyanogen bromide 
digestion products of the SN-SP-B fusion protein. The different fractions are displayed 
across the top and represent the same fractions from the elution profile in Figure 17. 
The outside lanes contain size reference markers with the size of each marker in kDa 
displayed down the sides of the gel. The gel was stained with CBB R250. The break 
between the last two lanes is due to a portion of the gel being removed from the image.!
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Figure 19: A Western blot analysis of various elution fractions from the LH20 size 
exclusion chromatography of the cyanogen bromide digestion products of the SN-SP-B 
fusion protein. The bands represent the antigen-antibody binding of the anti-SP-B 
antibody. The different fractions are displayed across the top and represent the same 
fractions from the elution profile in Figure 17. The outside lanes contain size reference 
markers with the size of each marker in kDa displayed down the sides of the 
membrane. The break between the last two lanes is due to a portion of the membrane 
being removed from the image.!
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3.5 Functional Studies of Recombinant SP-B"
" With a partially enriched recombinant SP-B, I moved onto functional studies. 
These studies were done to compare the activity of the expressed SP-B with native SP-
B  obtained from porcine lung lavages to ensure this recombinant expression was a 
viable source for functional SP-B. These functional studies include membrane leakage 
and lipid fusion assays as well as surface activity studies with a captive bubble 
surfactometer (CBS). All of these studies were conducted in the Jesus Perez-Gil lab at 
the Universidad Complutense de Madrid (Madrid, Spain)."
!
3.5.1 Leakage Assay"
! This experiment is designed to measure the ability of a molecule to disrupt a 
membrane enough to cause the interior environment to leak out. It is measured through 
the use of the fluorophores ANTS and DPX which are encapsulated inside LUVs (see 
Figure 20). While encapsulated, they are in enough proximity to one another for DPX to 
quench the fluorescence of ANTS. If these fluorophores were allowed to escape to the 
exterior environment, the diffusion would release ANTS from the quenching effects of 
DPX and an increase of ANTS fluorescence (520 nm) can be measured if excited at a 
wavelength of 353 nm. From this measurement, the percent leakage can be calculated. !
! Figure 21 compares the percent leakage of both the native and recombinant SP-
B samples. As the amount of SP-B increases (shown here as a protein:lipid mass ratio), 
the percent leakage also increases for both samples. However, the native SP-B causes 
more leakage than its recombinant counterpart. At an SP-B to lipid weight ratio of 0.13, 
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leakage has almost reached 100% whereas at the same amount the recombinant SP-B 
has only caused less than 60% leakage. !
! Figures 22 and 23 on the other hand show how percent leakage of both the 
native and recombinant SP-Bs respectively change over a period of five minutes. Once 
again this shows that while both cause leakage, the native SP-B does so much more 
efficiently. Interesting to note here is how the leakage of the native SP-B continues to 
increase over the full five minutes where in the recombinant SP-B experiment there is a 
sudden increase which promptly levels off. This seems to indicate that the native SP-B 
is creating a permanent pore in the membrane allowing continuous leakage to occur. 
This effect does not occur with the recombinant SP-B which only allows leakage to 
occur during an initial disruption of the membrane.!
!
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Figure 20: A schematic of the leakage assay. The blue circle represents the membrane 
of a LUV while the red and green dots represent the ﬂuorophores. After the addition of 
SP-B the membrane opens and the ﬂuorophores leak out to the surrounding 
environment.
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! !
Figure 21: The final percent leakage of both the native SP-B and recombinant SP-B 
leakage assays.!
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Figure 22: The percent leakage as a function of time of the leakage assay using native 
SP-B.!
!
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Figure 23: The percent leakage as a function of time of the leakage assay using 
recombinant SP-B.!
!
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3.5.2 Lipid Mixing"
! Like the leakage assay, lipid mixing also makes use of LUVs, however, this 
experiment measures the ability of a molecule to cause the lipids in the vesicles to mix. 
LUVs are formed with the FRET pair Rhodamine and NBD embedded directly into the 
membrane. FRET (fluorescence resonance energy transfer) is a technique in which the 
energy of a donor fluorophore is transferred to acceptor fluorophore in a radiation-less 
process. This will only occur if the fluorophores are in close enough proximity to one 
another. In this case, NBD is the donor fluorophore and Rhodamine is the acceptor 
fluorophore. When the average distance between these molecules is small enough, an 
emission close to the normal emission of Rhodamine (585 nm) can be measured. 
However, when the average distance increases, the 585 nm measurement will decrease 
while an emission close to that of NMD alone (470 nm) will increase. !
! During the initial phase of the experiment, labelled LUVs are mixed with an 
excess on unlabelled LUVs. Because both NBD and Rhodamine are contained within 
the membranes of the labelled vesicles, they are close enough for the FRET 
phenomenon to occur. However, if lipids are allowed to freely exchange between the 
vesicles, then the fluorophores will be diluted throughout the entire lipid mixture and the 
average distance will increase. This will be observed as a decrease in the 585 nm 
emission peak and an increase in the emission peak at 470 nm.!
! Figure 24 shows the fluorescent emission profile of the lipid mixing experiment 
using native SP-B. As the amount of SP-B increases, the Rhodamine peak (585 nm) 
decreases while the NBD peak (470 nm) increases. This demonstrates how SP-B is 
effective at causing lipid mixing. Figure 25 shows the same experiment with the 
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recombinant SP-B. While the same effect can be observed, it takes 4 μM of 
recombinant SP-B to achieve the same decrease in emission at 585 nm induced by only 
2 μM of native SP-B. This indicates that while the recombinant SP-B has SP-B activity, it 
is not as effective as the native SP-B.!
!
!
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Figure 24: The fluorescent profile of the lipid mixing assay with native SP-B at different 
concentrations. The fluorescence is a relative value and the wavelength is in nm. !
!
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Figure 25: The fluorescent profile of the lipid mixing assay with recombinant SP-B at 
different concentrations. The fluorescence is a relative value and the wavelength is in 
nm.!
!
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3.5.3 Captive Bubble Surfactometer (CBS)"
 The captive bubble surfactometer is a device used to measure the surface tension of a 
bubble sealed in a chamber. This bubble can act as a mimic of the inside of an alveolus 
and thus produces some of the most physiologically relevant experiments when working 
with lung surfactant. I have performed three different experiments with the CBS. These 
include initial absorption (IA), post expansion absorption (PEA), and dynamic 
simulations. As mentioned in the Materials and Methods, the recombinant SP-B 
samples displayed an inability to adhere to the air-water interface when injected below 
the bubble. This problem was partially mediated by injecting the sample directly into the 
air-water interface by touching the bubble with the micro-syringe during injection. 
Because of this, the data displayed below includes both injection techniques (touching 
bubble and not touching bubble).! !
!
3.5.3.1 Initial Absorption (IA)"
! With initial absorption experiments, the sample was injected and the surface 
tension measurements begin immediately and continued for 5 minutes. This experiment 
measures the ability of the sample to adhere and spread across an air-water interface 
and reduce its surface tension. This is much like what occurs when newly formed 
surfactant must locate and spread across the air-water interface in alveoli. Figures 26 
and 27 show the surface tension changes during this experiment. The surface tension 
generally starts at around 70 mN/m which is the normal surface tension of water. In both 
experiments, lipids alone do little to affect the surface tension of the interface which 
indicates that any pronounced change is due to the protein in the sample. In the not 
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touching bubble experiment (Figure 26), 2% native SP-B (nSP-B) reduces the surface 
tension to around 25 mN/m which is about the same level achieved by normal lung 
surfactant. The recombinant SP-B (rSP-B) is much less effective in this regard. Even at 
an amount of 10% of the total lipid mass, the surface tension is much greater than that 
achieved by the native SP-B.  However, when the samples were injected directly into 
the air-water interface (Figure 27), the recombinant SP-B performs much better and is 
seen producing surface tensions as low as normal surfactant. However, much more 
recombinant SP-B is required than the native SP-B (10% vs. 1%). While the 
recombinant SP-B can reduce surface tension in this experiment, it is less effective than 
native SP-B.  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Figure 26: The changes in surface tension during the initial absorption experiments (not 
touching bubble). These samples have been injected below the air-water interface. 
Error bars represent one standard deviation with a sample size: n=3.!
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Figure 27: The changes in surface tension during the initial absorption experiments 
(touching bubble). These samples have been injected directly into the air-water 
interface. Error bars represent one standard deviation with a sample size: n=3.  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3.5.3.2 Post Expansion Absorption (PEA)"
! Post expansion absorption uses a bubble that already has a sample spread 
across its air-water interface. The bubble is expanded, effectively increasing the surface 
area of the interface, and the surface tension is measured over the course of five 
minutes. What this experiment studies is the ability of the sample to diffuse across this 
enlarged surface area and reduce the surface tension of the interface back to normal. 
This is analogous to what occurs inside an alveolus when a deep breath is taken. The 
results of this experiment can be seen in Figures 28 and 29. Once again, the lipids 
alone do very little, indicating surface activity observed in the other samples require 
protein as well as the lipids. Like the IA experiments, the recombinant SP-B is not very 
effective unless the sample had been injected directly into the interface. When injected 
this way, both the recombinant and native SP-B allow the surface tension to return to 
rest at about 25 mN/m, which is similar to native surfactant. However, much more 
recombinant SP-B is required to be as effective as the native (up to 10 times). The 
same conclusion from the IA experiments can be drawn here. While not as effective as 
native SP-B, the recombinant SP-B still shows signs of being capable of normal 
surfactant function.  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Figure 28: The changes in surface tension during the post expansion absorption 
experiments (not touching bubble). These samples have been injected below the air-
water interface. Error bars represent one standard deviation with a sample size: n=3.!
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Figure 29: The changes in surface tension during the post expansion absorption 
experiments (touching bubble). These samples have been injected directly into the air-
water interface. Error bars represent one standard deviation with a sample size: n=3.!
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3.5.3.3 Dynamic Simulation"
!  With dynamic simulation experiments, the bubble already has a sample spread 
across the air-water interface. The bubble is then contracted and expanded 20 times 
over the course of a minute, which is the same rate as normal human breathing. This 
experiment imitates the alveolar environment during breathing and measures the 
changes in surface tension and relative surface area of the interface. Results from the 
dynamic simulation experiments are shown in Figures 30–38. !
! There are three things to look for in these experiments to assess if the surfactant 
is working properly. The first is maximum surface tension, which should not rise above 
the normal resting levels, which for normal surfactant is around 25 mN/m. The second is 
minimal surface tension, which should drop to almost 0 mN/m. The final thing to look for 
is the absence of hysteresis. Hysteresis is work applied to the bubble that does not 
result in a decrease in surface tension. In other words, it is a change in the relative area 
without change in the surface tension and can be observed in the following data as 
space between the compression and expansion lines. Normal working surfactant 
produces minimal hysteresis. If all three criteria are met, the sample is acting as an 
effective surfactant. !
! It is important to note here that the first cycle is usually less efficacious than the 
subsequent cycles and results in considerable hysteresis. This is due to the formation of 
multi-layered structures that are assembled underneath the interface during the first 
compression cycle and were discussed in the introduction (Figure 3). These structures 
create a reservoir for the surfactant to be stored during compression and allow the 
surfactant to easily re-spread along the interface during expansion. After the first cycle, 
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the formation of the multi-layered structures will occur more easily and will result in the 
disappearance of the hysteretic effect if the surfactant is functioning normally.!
! Figure 30 and 31 show the effect of lipids alone during compression-expansion 
cycles. None of the three criteria mentioned above are met in either trial. The maximum 
and minimum surface tension is too high and considerable hysteresis can be observed 
in every cycle. Therefore, the positive effect produced in the following experiments 
involving SP-B must be the result of the protein present in the samples.!
! The native SP-B produces positive results in almost every experiment (Figures 
32-34). The best results can be seen Figure 32. Other than the first cycle, all three 
criteria of a functional surfactant are met. The surface tension does not rise much above 
25 mN/m and drops to nearly 0 mN/m during compression. There is no space present 
between the expansion and compression lines in cycles 10 and 20, therefore no 
hysteresis is produced. !
! The results indicate the recombinant SP-B samples were not nearly as effective 
(Figures 35-38). Both 5% samples and the 10% not touching bubble samples produced 
results similar to lipids alone indicating that in these cases the SP-B was almost entirely 
not functional. However, some positive results can be seen in the 10% touching bubble 
experiment (Figure 38). Here we see the maximum surface tension rise not far above 
40 mN/m and drop to close to 0 mN/m during compression. This could, however, be due 
to over compression of the sample during the experiment.!
! These experiments show that surface activity can be observed using 
recombinant SP-B. However, in order to achieve this activity, much more protein is 
required and the sample must be directly applied to air-water interface. Even with these 
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added requirements, the effectiveness of recombinant SP-B never reached that of the 
native SP-B in dynamic simulation experiments.!
! These functional studies show the recombinant SP-B produces normal SP-B 
activity. This is encouraging as it demonstrates that a functional SP-B can be produced 
in a recombinant system which has never been done before.  However, while effective, 
it is never achieves the same results as native SP-B. Reasons for this are explored in 
the upcoming discussion.!
! !
!
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Figure 30: The dynamic simulation of the lipids alone sample that had been injected 
below the air-water interface (ie. not touching the bubble). The graph shows the surface 
tension and surface area changes of the air-water interface during cycles 1, 10, and 20.!
!
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Figure 31: The dynamic simulation of the lipids alone sample that had been injected 
directly into the air-water interface (ie. touching the bubble). The graph shows the 
surface tension and surface area changes of the air-water interface during cycles 1, 10, 
and 20.!
!
Dynamics Trial 1
Relative Area
0.0 0.2 0.4 0.6 0.8 1.0 1.2
S
ur
fa
ce
 T
en
si
on
 (m
N
/m
)
0
20
40
60
80
Cycle 1
Cycle 10
Cycle 20
Dynamics Trial 2
Relative Area
0.0 0.2 0.4 0.6 0.8 1.0 1.2
S
ur
fa
ce
 T
en
si
on
 (m
N
/m
)
0
20
40
60
80
Cycle 1
Cycle 10
Cycle 20
Dynamics Trial 1
Relative Area
0.0 0.2 0.4 0.6 0.8 1.0 1.2
S
ur
fa
ce
 T
en
si
on
 (m
N
/m
)
0
20
40
60
80
Cycle 1
Cycle 10
Cycle 20
Dynamics Trial 1
Relative Area
0.0 0.2 0.4 0.6 0.8 1.0 1.2
S
ur
fa
ce
 T
en
si
on
 (m
N
/m
)
0
20
40
60
80
Cycle 1
Cycle 10
Cycle 20
Dynamics Trial 2
Relative Area
0.0 0.2 0.4 0.6 0.8 1.0 1.2
S
ur
fa
ce
 T
en
si
on
 (m
N
/m
)
0
20
40
60
80
Cycle 1
Cycle 10
Cycle 20
Dynamics Trial 1
Relative Area
0.0 0.2 0.4 0.6 0.8 1.0 1.2
S
ur
fa
ce
 T
en
si
on
 (m
N
/m
)
0
20
40
60
80
Cycle 1
Cycle 10
Cycle 20
 93
  !
Figure 32: The dynamic simulation of the 1% native SP-B sample that had been injected 
below the air-water interface (ie. not touching the bubble). The graph shows the surface 
tension and surface area changes of the air-water interface during cycles 1, 10, and 20. 
The SP-B concentration is a percentage of the total lipid mass.!
!
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Figure 33: The dynamic simulation of the 1% native SP-B sample that had been injected 
directly into the air-water interface (ie. touching the bubble). The graph shows the 
surface tension and surface area changes of the air-water interface during cycles 1, 10, 
and 20. The SP-B concentration is a percentage of the total lipid mass.!
!
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Figure 34: The dynamic simulation of the 2% native SP-B sample that had been injected 
below the air-water interface (ie. not touching the bubble). The graph shows the surface 
tension and surface area changes of the air-water interface during cycles 1, 10, and 20. 
The SP-B concentration is a percentage of the total lipid mass. !
!
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Figure 35: The dynamic simulation of the 5% recombinant SP-B sample that had been 
injected below the air-water interface (ie. not touching the bubble). The graph shows the 
surface tension and surface area changes of the air-water interface during cycles 1, 10, 
and 20. The SP-B concentration is a percentage of the total lipid mass.!
!
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Figure 36: The dynamic simulation of the 5% recombinant SP-B sample that had been 
injected directly into the air-water interface (ie. touching the bubble). The graph shows 
the surface tension and surface area changes of the air-water interface during cycles 1, 
10, and 20. The SP-B concentration is a percentage of the total lipid mass.!
!
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Figure 37: The dynamic simulation of the 10% recombinant SP-B sample that had been 
injected below the air-water interface (ie. not touching the bubble). The graph shows the 
surface tension and surface area changes of the air-water interface during cycles 1, 10, 
and 20. The SP-B concentration is a percentage of the total lipid mass.!
!
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Figure 38: The dynamic simulation of the 10% recombinant SP-B sample that had been 
injected directly into the air-water interface (ie. touching the bubble). The graph shows 
the surface tension and surface area changes of the air-water interface during cycles 1, 
10, and 20. The SP-B concentration is a percentage of the total lipid mass.!
!
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4.! Discussion!!!
! In order to gain further understanding of lung surfactant function, it is crucial to 
determine the mechanism of SP-B. A prerequisite to a mechanistic understanding of a 
protein is to first determine its three dimensional structure as the structure and function 
of proteins are forever tied together. SP-B is a rare case in that it is an essential protein 
that does not yet have a solved three dimensional structure. The absence of a structure 
is not from a lack of trying, however, as researchers have been attempting to solve this 
problem for many years. Reasons why this has failed were discussed in the introduction 
and include the difficulty of getting SP-B to crystallize (which is required for X-ray 
crystallography) and the difficulty with recombinant expression (which is required for 
three dimensional NMR). In this thesis, I have discussed a renewed effort in the latter.!
! Previous attempts to produce a recombinant SP-B involved the fusion to SN with 
a thrombin cleavage site between them. Only a small amount of expression was 
achieved 81. As mentioned in the results, a new plasmid was designed that replaced the 
thrombin cleavage site with a cyanogen bromide cleavage site (methionine residue). 
Also the histidine tag was moved from the amino-terminus to the carboxy-terminus and 
seven residues were deleted from the amino-terminus of SP-B. Once transformed into 
C43 E. coli, these changes resulted in an increased expression of the SN-SP-B fusion, 
much of which was present in insoluble inclusion bodies (see Figure 2). The new 
cyanogen bromide cleavage also produced positive results (see Figure 6) in which the 
fusion protein is almost entirely cleaved and SP-B alone and can be observed on a 
Western blot with an anti-SP-B antibody. This is the first time that a recombinantly 
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expressed SP-B has been observed on a SDS polyacrylamide gel or Western blot. 
While not yet purified, this was a very encouraging result.!
! While working with the new plasmid, something unexpected occurred. Another 
protein from the cellular extract was binding to the nickel-bound IMAC column and 
eluting just before the SN-SP-B fusion (see Figures 6 and 7). Western blotting with an 
anti-SP-B antibody confirms that this other peptide contains SP-B (see Figure 8). The 
size estimates seem to indicate that this alternate peptide could be SP-B expressed 
alone. This alternate expression was very puzzling as the plasmid was designed to only 
allow production of the SN-SP-B fusion and earlier studies have shown that a similar 
plasmid with no SN produces no detectable levels of SP-B. To try to arrive at a possible 
explanation, original SN-Δ7NTΔM-SP-B-6His plasmid construct (Figure 39) was 
studied. An important feature to the plasmid construct is the ribosome binding site (also 
known as the Shine-Delgarno sequence) which is located 3’ (upstream) of the start 
codon (ATG) 86. After the gene undergoes transcription, the resulting mRNA is directed 
to a ribosome which binds at the ribosome binding sequence before translation takes 
place. In this construct, the ribosome binding site is the sequence GAAGGAG and its 
location is highlighted in Figure 40. To see if SP-B could be expressed without the 
fusion, I scanned the plasmid upstream of the SP-B gene for another possible ribosome 
binding site. I found a possible site that has the sequence GGAG and is also highlighted 
in Figure 39. While only a partial match for a ribosome binding site, it has previously 
been demonstrated that small fragments of ribosome binding sites can lead to alternate 
gene expressions 86. If this sequence does act as a secondary ribosome binding site, 
then translation would begin at the next start codon (ATG) which in this case would the 
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ATG in between the SN and SP-B genes that normally encodes the cyanogen bromide 
cleavage site. If translation were to occur here, it would produce SP-B with the carboxy-
terminal histidine tag. This would produce a protein that would stick to the nickel-bound 
IMAC resin and would explain the presence of the SP-B positive band in the Western 
blot. !
! Another possible explanation for the alternate expression would be uncontrolled 
proteolysis inside the cell. The identity of this alternate expression could be found using 
accurate mass analysis or amino-terminal sequencing.!
!
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Figure 39: The SN-7NTM-SP-B-6His plasmid construct with ribosome binding site. 
This ﬁgure is similar to Figure 1 except the amino acid sequence is omitted and part of 
the DNA sequence 3’ (upstream) of the start of the SN gene is included to show the 
location and identity of the ribosome binding site. Also highlighted here is a possible 
secondary ribosome binding site that is located within the SN sequence 3’ to the start of 
the SP-B gene which could be responsible for SP-B-6His expression.
GAAGGAGATATAGATATACATATGGCAACTTCAACTAAAAAATTACATAAAGAACCTGCGACTT
TAATTAAAGCGATTGATGGTGATACGGTTAAATTAATGTACAAAGGTCAACCAATGACATTCAG
ACTATTATTGGTTGATACACCTGAAACAAAGCATCCTAAAAAAGGTGTAGAGAAATATGGTCCT
GAAGCAAGTGCATTTACGAAAAAAATGGTAGAAAATGCAAAGAAAATTGAAGTCGAGTTTGACA
AAGGTCAAAGAACTGATAAATATGGACGTGGCTTAGCGTATATTTATGCTGATGGAAAAATGGT
AAACGAAGCTTTAGTTCGTCAAGGCTTGGCTAAAGTTGCTTATGTTTACAAACCTAACAATACA
CATGAACAACATTTAAGAAAAAGTGAAGCACAAGCGAAAAAAGAGAAATTAAATATTTGGAGCG
AAGACAACGCTGATTCGGGCCTGATGTGCTGGCTGTGCCGCGCGCTGATCAAACGCATCCAGGC
CCTGATTCCGAAAGGTGCGCTGGCTGTGGCAGTGGCCCAGGTGTGCCGCGTGGTGCCGCTGGTG
GCGGGCGGCATCTGCCAGTGCCTGGCGGAACGCTATAGCGTGATCCTGCTGGATACCCTGCTGG
GCCGCCTGCTGCCGCAGCTGGTGTGCCGCCTGGTCCTGCGTTGCAGCATGCACCATCACCACCA
TCATTAAGGATCC
Ribosome Binding Site
GGAGC
GAAGGAGA
Possible Secondary
Ribosome Binding Site
    =SN
    =7NTM-SP-B
    =NdeI restriction site
    =BamH1 restriction site
    =6His tag
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! While the successful expression and cleavage of the recombinant SP-B was very 
promising, the SP-B had to be separated from the SN fragments and other impurities to 
be of any use for experimental and clinical applications. The enrichment of recombinant 
SP-B would prove to be very difficult. Unsurprisingly, due to SP-Bs high hydrophobic 
content, it has a tendency to aggregate. After the cleavage and subsequent dialysis, it is 
probable that the SP-B formed large protein aggregates, which resulted in a sample that 
was very difficult to work with and remained insoluble in most aqueous and organic 
solvents. This led to many problems during isolation procedures that can be seen in the 
work done with organic extraction, HPLC, and cationic exchange chromatography (see 
Figures 10-14). A breakthrough occurred with a new solubilization procedure in which 
the protein was first dissolved in a high concentration of urea and dialyzed in the 
presence of DPPC vesicles, followed by lyophilization. The solubilized SP-B had 
presumably bound to the vesicles and remained inside the dialysis tubing while the urea 
diffused out. The dried protein/lipid powder was then easily solubilized in organic 
solvent. Being in solution with organic solvent does not help with many of the 
techniques tried (ie. HPLC, anionic exchange chromatography) as the solvent is not 
compatible with these methods. However, this breakthrough allowed the use of LH20 
resin, which is resistant to organic solvent, to achieve partial enrichment of the 
recombinant SP-B (see Figures 17 and 18). While not completely isolated, this was the 
highest enrichment of recombinant SP-B yet obtained, so it was decided to proceed with 
functional studies to find out if the recombinant SP-B had the ability to function like 
native SP-B. This is very important for any possible clinical applications.!
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! The problem with partial enrichment could be addressed by making a new 
construct where the his-tag is retained on the SP-B after SN cleavage. The SP-B could 
then be enriched using another Ni column thus circumventing the LH20 chromatography 
altogether.!
! Functionally, we already know that SP-B has the ability to bind and disrupt 
membranes, fuse membranes together, and reduce surface tension of air-water 
interfaces 47 48 49 50 51. Going into the functional work, it was known that the function of 
the recombinant SP-B could be impaired. First of all, the impurities still present could 
have an impact. Also, there was as yet no attempt to ensure the recombinant SP-B was 
properly folded. Structural work has yet to be accomplished so it is entirely possible that 
during the harsh conditions of purification, the recombinant SP-B could be folded in a 
non-native state which would impair its functional ability. Lastly, and possibly the most 
important, is the amino-terminal deletion. !
! As mentioned in the results, this new SN-Δ7NTΔM-SP-B-6His the seven amino-
terminal residues of SP-B was removed from the plasmid construct due to a suggestion 
by Sharifahmadian (2013) that this modification could allow for SP-B to be more easily 
expressed 81. As the primary goal of this work is to solve the three-dimensional structure 
of SP-B, it was decided that these seven residues were not necessary. It is already 
known that these residues have to remain outside the first alpha helix of SP-B due to its 
proline rich structure (FPIPLPY) so its removal should have very little impact on the 
overall tertiary structure. It is thought that these residues will form a kinked, poly-pro like 
structure that will stick out from the rest of the protein 48 87. While not impacting the 
tertiary structure of SP-B, this amino-terminal region has been shown to have a large 
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functional impact. The lack of an amino-terminal region has been shown to impact the 
ability of SP-B to cause membrane leakage and lipid mixing 48, as well as lowering SP-
Bs ability to reduce surface tension in CBS experiments 17 87. Molecular dynamics 
simulations suggest that the amino-terminal region also has very important role on 
membrane binding 87 88. While these abilities were impaired with the removal of the 
amino-terminus, there was still some function present. This previous work utilized SP-B 
fragments as recombinant expression was not yet possible and native SP-B was only 
available full length. !
! Because of these previous results, the recombinant amino-term deleted SP-B 
was not expected to be as functional as native SP-B. However, some SP-B activity was 
observed with the recombinant samples. This result supports the conclusion that the 
method of expressing recombinant SP-B presented in this thesis is a viable source of 
SP-B for experimental and clinical applications. As seen in the results of the functional 
studies (leakage assay, lipid mixing, and CBS), we can clearly see that, while impaired, 
the recombinant SP-B does retain some SP-B activity.!
! The leakage assay experiments produced an interesting result. With the native 
SP-B samples, a steady increase of leakage was observed over a period of five minutes 
(Figure 22). This indicates that the native SP-B is causing an open pore to form in the 
membrane which allows the interior environment to continuously leak out. This 
increasing leakage is not seen with the recombinant SP-B samples (Figure 23) 
suggesting that in this case, pore formation does not occur. One of the main differences 
in the samples is the aforementioned lack of the seven amino terminal residues in the 
recombinant SP-B. It can be concluded from this that these residues are important in 
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pore formation in lipid films. This conclusion is supported by molecular dynamics 
simulations 88. However, it is important to mention that this difference could also be 
caused by misfolding in the recombinant SP-B or impurities present in the recombinant 
sample. !
! The lipid mixing results were less promising than the leakage. While some small 
level of activity was observed with the recombinant SP-B, it was nowhere near as 
effective as the native SP-B sample (Figures 24 and 25). Similar results were found in 
experiments with SP-B fragments 48. Ryan et al. found that with the leakage assay, the 
fragment without the amino-terminus retained some activity however, in the lipid mixing 
experiments it did not. They concluded that the amino-terminus was more important to 
lipid mixing than leakage which seems to be replicated in the experiments presented in 
this thesis. Once again, the loss of activity in the recombinant SP-B sample could also 
be due to misfolding and the presence of impurities.!
! In the CBS experiments, we also see SP-B activity with the recombinant 
samples. However, once again there was only partial activity when compared with 
native SP-B (Figures 26-38). This comes as no surprise because of the reasons listed 
above, though there were interesting observations. First of all, the recombinant samples 
were only effective when injected directly into the air-water interface. This could indicate 
that the recombinant SP-B has trouble allowing the surfactant to adhere to the interface 
and suggests this is another function of the amino-terminus. Another interesting 
observation was that during dynamic simulation experiments, hysteresis did not 
disappear after the first cycle in recombinant SP-B (Figure 38) as is usually the case 
with native SP-B samples (Figure 32). As mentioned in the results, the hysteresis is a 
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result of the multi-layered structures being organized underneath the air-water interface. 
This process is normally facilitated by SP-B (Figure 3) and once this is accomplished in 
the first compression-expansion cycle, it occurs much easier in subsequent cycles 
resulting in the disappearance of hysteresis (ie. the space between the compression 
and expansion lines in Figures 32 and 38). The fact that hysteresis is always present 
with the recombinant sample demonstrates an inability of the recombinant SP-B to 
properly form the multi-layered structures. This represents another possible function of 
the amino-terminus of SP-B. However, it must be emphasized that this assumption is 
not conclusive as this impairment could also be due to misfolding and the presence of 
impurities in the recombinant SP-B sample.!
! In this thesis, I have described a novel method for the expression and partial 
enrichment of a recombinant SP-B. I have also demonstrated that this recombinant SP-
B retains some portion of native SP-B activity. Therefore, this technique shows promise 
that it can be developed into a viable source of SP-B for various experimental as well as 
clinical applications. Furthermore, the data emphasizes the importance of the amino-
terminus to SP-B function. While the results of this thesis are very encouraging, more 
work is needed for this work to progress further. First of all, the conclusion that the 
impairment of the recombinant SP-B function is due to the amino-terminal deletion 
remains questionable because of the presence of impurities and the possibility of 
misfolding. To remove this doubt, a new plasmid could be designed that leaves the 
amino-terminus intact. Expression and enrichment of this full length SP-B can be done 
using the same conditions and procedures described here. Therefore, the sample of 
recombinant SP-B should fold the same way and contain the same impurities as the 
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sample used in these functional experiments except in this case, the SP-B would have 
its amino-terminus. Any difference observed in the activity between this SP-B and the 
amino-terminal deleted SP-B should be entirely due to the amino-terminus and remove 
the possible effects of misfolding and impurities out.!
! To solve the problem with purification, one solution could be to try to reduce the 
number of lyophilization steps which is likely resulting in much of the aggregation that is 
making the recombinant SP-B very difficult to work with. It is probably necessary to 
revisit the plasmid and design one better suited for enrichment. !
! One of the main sources of impurities are the SN fragments and incomplete 
digests that result from the cyanogen bromide cleavage. Some of these impurities are 
similar in size to SP-B which can make separation difficult. To work around this, a 
plasmid can be designed in which the methionine residues in SN are mutated. A 
possible design is shown in Figure 40 in which the four internal methionine residues of 
SN are mutated to alanine as seen in 89. When the resulting gene is cleaved, the 
resulting products should include SP-B (~8 kDa), SN (~18 kDa), and if the reaction does 
not go to completion, undigested SN-SP-B (~26 kDa). With only three products of very 
different sizes, the separation should be much easier to achieve. !
! !
!
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Figure 40: Possible future plasmid construct with methionine mutation in SN. Similar to 
SN-Δ7NTΔM-SP-B-6His (Figure 4) however the interior methionine residues have been 
mutated to alanine. Mutated residues are highlighted in red boxes.!
!
ΔM-SN-Δ7NTΔM-SP-B-6His-codop
CATATGGCAACTTCAACTAAAAAATTACATAAAGAACCTGCGACTTTAATTAAAGCGATTGATG
    M  A  T  S  T  K  K  L  H  K  E  P  A  T  L  I  K  A  I  D    
GTGATACGGTTAAATTAGCGTACAAAGGTCAACCAGCGACATTCAGACTATTATTGGTTGATAC
G  D  T  V  K  L  A  Y  K  G  Q  P  A  T  F  R  L  L  L  V  D  T
ACCTGAAACAAAGCATCCTAAAAAAGGTGTAGAGAAATATGGTCCTGAAGCAAGTGCATTTACG
  P  E  T  K  H  P  K  K  G  V  E  K  Y  G  P  E  A  S  A  F  T
AAAAAAGCGGTAGAAAATGCAAAGAAAATTGAAGTCGAGTTTGACAAAGGTCAAAGAACTGATA
 K  K  A  V  E  N  A  K  K  I  E  V  E  F  D  K  G  Q  R  T  D 
AATATGGACGTGGCTTAGCGTATATTTATGCTGATGGAAAAGCGGTAAACGAAGCTTTAGTTCG
K  Y  G  R  G  L  A  Y  I  Y  A  D  G  K  A  V  N  E  A  L  V  R
TCAAGGCTTGGCTAAAGTTGCTTATGTTTACAAACCTAACAATACACATGAACAACATTTAAGA
  Q  G  L  A  K  V  A  Y  V  Y  K  P  N  N  T  H  E  Q  H  L  R
AAAAGTGAAGCACAAGCGAAAAAAGAGAAATTAAATATTTGGAGCGAAGACAACGCTGATTCGG
 K  S  E  A  Q  A  K  K  E  K  L  N  I  N  S  E  D  N  A  D  S  
GCCTGATGTGCTGGCTGTGCCGCGCGCTGATCAAACGCATCCAGGCCCTGATTCCGAAAGGTGC
G  L  M  C  W  L  C  R  A  L  I  K  R  I  Q  A  L  I  P  K  G  A  
GCTGGCTGTGGCAGTGGCCCAGGTGTGCCGCGTGGTGCCGCTGGTGGCGGGCGGCATCTGCCAG
  L  A  V  A  V  A  Q  V  C  R  V  V  P  L  V  A  G  G  I  C  Q  
TGCCTGGCGGAACGCTATAGCGTGATCCTGCTGGATACCCTGCTGGGCCGCCTGCTGCCGCAGC
 C  L  A  E  R  Y  S  V  I  L  L  D  T  L  L  G  R  L  L  P  Q  
TGGTGTGCCGCCTGGTCCTGCGTTGCAGCATGCACCATCACCACCATCATTAAGGATCC
L  V  C  R  L  V  L  R  C  S  M  H  H  H  H  H  H  STOP
    =SN
    =Δ7NTΔM-SP-B
    =NdeI restriction site
    =BamH1 restriction site
    =6His tag
Notes:
SN-SP-B fusion protein with a C-term 6His tag. The SN contains 4 
point mutations (26M"A, 32M"A, 65M"A, 98M"A). The SP-B contains 
a 7 amino acid deletion of the N-terminus as well as 2 point 
mutations (21M"L, 58M"L). Has a Met residue between the SN and 
SP-B as well a between the SP-B and 6His tag to facilitate CNBr 
cleavage. Also contains Nde1 and BamH1 restriction sites. 
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! The expression of SP-B alone could provide another possibility. It was thought 
that SP-B could not be expressed without a fusion protein due to its very hydrophobic 
nature however its expression alone here proves otherwise. The SP-B expressed in this 
way only occurs in small quantities and is always contaminated with the SN-SP-B 
fusion. It is possible that if a plasmid is designed containing just SP-B with a histidine 
tag, it could result in the expression of an easily enriched recombinant SP-B (Figure 41). 
If the presence of a ribosome binding site fragment is enough to express a small 
amount of SP-B, then perhaps the full length ribosome binding site in the correct 
location 3’ of the start of the SP-B gene would produce enough recombinant SP-B to 
work with. !
! !
!
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Figure 41: Possible future plasmid construct containing just the SP-B gene with a 
carboxy-terminal histidine tag.!
!
Δ7NTΔM-SP-B-6His-codop
CATATGTGCTGGCTGTGCCGCGCGCTGATCAAACGCATCCAGGCCCTGATTCCGAAAGGTGCGC
    M  C  W  L  C  R  A  L  I  K  R  I  Q  A  L  I  P  K  G  A
TGGCTGTGGCAGTGGCCCAGGTGTGCCGCGTGGTGCCGCTGGTGGCGGGCGGCATCTGCCAGTG
L  A  V  A  V  A  Q  V  C  R  V  V  P  L  V  A  G  G  I  C  Q  C
CCTGGCGGAACGCTATAGCGTGATCCTGCTGGATACCCTGCTGGGCCGCCTGCTGCCGCAGCTG
  L  A  E  R  Y  S  V  I  L  L  D  T  L  L  G  R  L  L  P  Q  L
GTGTGCCGCCTGGTCCTGCGTTGCAGCATGCACCATCACCACCATCATTAAGGATCC
 V  C  R  L  V  L  R  C  S  M  H  H  H  H  H  H  STOP
    =Δ7NTΔM-SP-B
    =NdeI restriction site
    =BamH1 restriction site
    =6His tag
Notes:
SP-B with a C-term 6His tag. The SP-B contains a 7 amino acid 
deletion of the N-terminus as well as 2 point mutations (21M"L, 
58M"L). Also contains N e1 and BamH1 restric ion sites. 
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! Using the methods described above, producing an enriched recombinant SP-B 
sample is a distinct possibility. Once this has been achieved, SP-B can be expressed in 
the presence of 15N and 13C isotopes which would allow for three dimensional NMR and 
solving the tertiary structure of SP-B. This would greatly help our understanding of SP-B 
function as well as our understanding of surfactant as a whole. !
! Other methods that could be used to assess the structure of the recombinant SP-
B would be circular dichromism (CD) and Fourier resonance infrared spectroscopy 
(FTIR). Both methods can give information related to the secondary structure of 
proteins. Previous experiments using native SP-B dissolved in an acetonitrile solution 
have indicated that SP-B has a largely alpha helical confirmation 90. These experiments 
could be repeated using recombinant SP-B in the same conditions. By comparing the 
results to the native SP-B experiments, we can determine if the recombinant SP-B is 
structurally similar.!
! Finally, the ability to produce large quantities of enriched recombinant SP-B will 
have possible clinical applications. The recombinant SP-B could be used in future 
treatments for diseases such as RDS and ARDS. !
!
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